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The research presented in this thesis focuses on the identification and utilisation of
novel indices measured from tidal breathing expiratory flow patterns to assess airflow
obstruction in adults. The work is in two parts, firstly the development of the data collection
protocol and the identification of suitable indices and secondly the evaluation of the
reproducibility of these indices and their comparison with conventional indices and reported
symptoms.
The current routine method used to assess airflow obstruction is the measurement of
FEV], however this test requires patient understanding of the test procedure and maximal
effort to produce satisfactory results. Furthermore, forced expiration is not a breathing
manoeuvre that people perform in every day life. The usefulness of FEVi in assessing
reversibility to bronchodilation was studied in a retrospective study which showed that 41%
of patients who were identified as non-reversible by FEVi criteria showed reversibility of
forced or relaxed vital capacity, indicating that FEVi does not detect all the physiological
effects of bronchodilators. If tidal breathing is measured, a number of the disadvantages of
FEVi are overcome. It is effort-independent, requires no learning of special breathing
manoeuvres on the patient's part and so can be performed even in acutely breathless patients.
A method of recording tidal breathing patterns was developed in which the type of
equipment and the measurement protocol was comfortable for the subject, applicable to the
routine clinical setting and impacted minimally on the tidal breathing pattern. A five-minute
collection time was chosen, recorded after a two-minute acclimatisation period. A method of
producing an averaged breath was developed from which a number of novel tidal indices
could be measured. After analysis of these indices in pilot studies, three indices, (TBEV i
(volume of air exhaled in the first second of a tidal breath), TPEF (peak tidal expiratory flow
rate) and EF25 (expiratory flow at end tidal volume plus 25% end tidal volume) were
identified which changed consistently following bronchodilators and these were
subsequently studied in more depth. Each of these indices correlated with specific
conductance (sGaw) at baseline and showed significant increases after bronchodilator but not
after placebo treatment in patients known to have reversible airflow obstruction.
For the tidal breathing method to be clinical acceptable it had to be shown to be
reproducible and ideally to correlate with patient perceived breathlessness. The final section
of the thesis reports studies of reversibility of these measures. Reproducibility was similar to
conventional indices of airway obstruction.
In summary this thesis describes development of a method for the measurement and
analysis of tidal breathing expiratory flow patterns, which yields consistent and
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FEV, Volume expired in the first second of a forced expiration
FVC Forced vital capacity
RVC Relaxed vital capacity
PEFR Peak expiratory flow rate
MEFV Maximum expiratory flow volume




Tjot Total breath duration
Vt Tidal volume
f Breathing frequency
TC Breathing cycle duration (TE + Ti)
Vt/T, Mean inspiratory flow rate
Vt/Te Mean expiratory flow rate
VA Alveolar ventilation
VD Physiological dead space
TLC Total lung capacity
RV Residual volume
FRC Functional residual capacity
Vr Relaxation volume
MBD Mean breath duration
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Abbreviation Description
dlco Transfer factor of carbon monoxide
sGaw Specific conductance of the airways
Raw Airways resistance
Vtg Thoracic gas volume
co2 Carbon dioxide
o2 Oxygen
PaC02 Arterial carbon dioxide pressure
Pa02 Arterial oxygen pressure
COPD Chronic obstructive pulmonary disease
ASTER Harmonic analysis of the entire airflow profile
R.I.P. Respiratory inductance plethysmography
va/q Ventilation / perfusion ratio
MIGET Multiple inert gas elimination technique
Pdi Transdiaphragmatic pressure
TBFVL Tidal breathing flow volume loops
Tptef/TE Ratio of time needed to reach maximum expiratory flow to total
expiratory time
dV/VT Ratio of the volume expired before peak expiratory flow
achieved to expiratory volume
NEP Negative expiratory pressure
TBEVi The volume exhaled in the first second of a tidal breath
TPEF The peak tidal expiratory flow rate
TEEV, The volume exhaled in the last second of a tidal breath
ef25 Expiratory flow at end tidal volume plus 25% end tidal volume
Ve max Maximal expiratory flow
HPV Hypoxic pulmonary vasoconstriction
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Abbreviation Description
Trs The time constant of the respiratory system.
EV Extrapolated volume (the volume of dynamic hyperinflation)
PD2o Provocative dose which causes a 20% drop in FEY]
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Airflow obstruction is of importance in medicine because of the morbidity and
mortality associated with it. A survey by the Lung and Asthma Information Agency
showed that in the UK in males and females over 65 years old the crude mortality rates
from COPD were 48.2 and 22.5 per 10,000 respectively [1].
This thesis is concerned with the methods used to quantify airflow obstruction with
particular reference to novel methods of assessing obstruction from recordings of tidal
breathing.
1.2: Causes of Airflow Obstruction.
Chronic airflow obstruction occurs in a number of diseases including asthma,
emphysema, chronic bronchitis and cystic fibrosis, and it is therefore obvious that it is
caused by a number of different mechanisms, Comroe et al [2] list the main reasons that
airways become obstructed. These are: -
• Constriction of bronchiolar smooth muscle.
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• Mucosal congestion or inflammation.
• Oedema of bronchiolar tissues.
• Plugging of the lumen by mucus.
• Cohesion of mucosal surfaces by surface tension forces.
• Infiltration, compression or fibrosis of bronchioles.
• Collapse or kinking of bronchioles due to loss of radial traction and/or regional
variations in airway resistance.
One or more of the above may cause each disease state. However, whatever the
underlying cause of the obstruction the end results are: -
• A decrease in dynamic compliance due to an increase in total airways
resistance.
• Hyperinflation due to air trapping and loss of elastic lung recoil, which leads to
an increase in the work of breathing.
1.3: Why look at Spontaneous Breathing?: Problems with Forced
Expiration.
Since the 1960s the maximum expiratory flow volume (MEFV) curve has been
used as a method of quantifying of airflow obstruction [3]. The MEFV and maximum
expiratory flow time (MEFT) curves allow measurement of several variables, the main ones
being FEVi, FVC and PEFR. As these measurements have been used for many years they
are well understood and the normal ranges are well defined, however many groups e.g.
Burrows [4] and Mahler [5] have reported that these lung function tests correlate only
weakly or not at all [6] with the degree of dyspnoea experienced by a patient. It has also
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been reported by Smith [7] that patients tested for reversibility to bronchodilators
sometimes report symptomatic benefit but show no improvement in the conventional forced
expiratory variables.
The forced expiratory procedure can cause cough, wheeze and dynamic airway
collapse and is effort dependent and so false low results may be obtained.
It has also been shown that the "volume history" of the expiratory manoeuvre can
alter the results. Brusasco [8] studied the effect of inhalation to TLC in normal subjects
who performed maximal expiratory manoeuvres and partial expiratory manoeuvres before
and after inhalation of methacholine. They found that the maximal expiratory manoeuvre
showed significantly reduced RV compared to the partial manoeuvre both before and after
methacholine inhalation. In addition the flow rates were greater for the partial expiratory
manoeuvre with the differences increased after methacholine. They concluded that the
inspiration to TLC was causing stress relaxation in the airways.
Lim et al [9] examined the effects of volume history on asthmatics with both
spontaneous obstruction and acutely induced obstruction. They found that with
spontaneous obstruction Ve max (maximal expiratory airflow) was decreased after a deep
inhalation and that this decrease was directly related to the severity of the obstruction.
When acute obstruction was induced, either by cold air bronchoprovocation or doubling
doses of nebulised histamine Ve max was increased after a deep inhalation. They
suggested that the difference in the response in the two groups was due to differences in the
site of the obstruction.
Other studies have shown either no change [10], bronchoconstriction [11] or
bronchodilation [12] following inspiration to TLC in asthmatics. Fairshter [13] studied
airway hysteresis in normal subjects and patients with chronic airflow obstruction and
found that specific conductance (sGaw) increased after an inspiration to TLC and that the
increase was reduced as the time between the deep inspiration and sGaw measurement
increased. In patients with COPD the sGaw decreased after inspiration to TLC i.e. the deep
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inspiration caused bronchoconstriction. D'Angelo [14] found that in COPD patients the
type of inspiration prior to the forced expiration was important, they looked at the effect of
two different inspirations and found that expiratory flows were 20-40 % larger when
preceded by a rapid inspiration with no end inspiratory pause.
These unpredictable bronchoconstrictor or bronchodilator effects of volume history
will complicate the interpretation of FEVi and FVC measurements.
These limitations of forced expiration raise the question: Can useful measurements
be made of airflow obstruction from spontaneous (tidal) breathing?
1.4: Spontaneous Ventilation in Normal Subjects.
By convention the breathing pattern is described by the minute ventilation (VE) and
its components tidal volume (VT) and respiratory frequency (f). Other commonly used
descriptors of breathing pattern are time to expire (TE), time to inhale (Ti) and total breath
duration (TTOt)- In a study during which Priban [15] looked at different resting breathing
patterns in man he observed that although the breathing pattern at rest may seem regular,
close inspection showed small changes in the depth and rate of the breathing. In a later
study [16] he looked more closely at these changes and found that in 15/20 subjects VT and
f were negatively correlated at rest and, therefore, that the magnitude of the fluctuations in
ventilation were less than those of its components. He stated that the fluctuations occurring
in VT and f were too fast to be associated with a feedback loop involving the blood gas
tensions and more likely to be due to a behavioural control mechanism which maintains a
tidal volume and frequency at a level which minimises the work of breathing.
Newsom Davis and Stagg [17] went on to investigate the volume and time
components of the breathing pattern. They confirmed Priban's findings that VT and TTOt
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(reciprocal of f) were positively correlated, but found that there was an even stronger
positive correlation between VT and T] which implies that the mean rate of inspiration for
each breath (V,) is held relatively constant. The correlation between VT and TE was found
to be weaker than the VT - Ti correlation; this larger variation in TE was partly due to
swallowing and expiratory pauses. They stated that the tendency for ventilation to remain
constant depends primarily on the tendency for the V) to be held constant and that
variability in ventilation was due to uncorrelated scatter of TE with respect to VT. They also
observed subjects' breathing pattern during periods of CO2 rebreathe and found that minute
ventilation was increased by a increase in VT and shortening of TE, while the Ti stayed
relatively unchanged and that V) increased as inhaled CO2 level was raised.
Kay [18] also studied the relationship between VT, Ti and TE during rest and found
correlation between both VT and ^ and between VT and TE.
This early work on breathing pattern lead to the conclusion that mean inspiratory
flow (Vt/Ti) is set by the respiratory drive, and that mean expiratory flow (Vt/Te) reflects
the elastic recoil of the lungs.
In 1987 studies by Shea and Benchetrict showed that individuals possess a
characteristic breathing pattern not only in terms of the standard respiratory variables [19],
but also in terms of the shape of the entire airflow profile as quantified by harmonic
analysis (ASTER) [20] and that the breathing pattern is highly conserved over time [21].
Further to this work in 1989 Shea et al [22] studied the breathing pattern of adult identical
twins and found that there were highly significant similarities within twin pairs compared
to random pairs of two individuals from the same population.
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1.5: Spontaneous Ventilation in Patients with Airflow Obstruction.
A few groups have looked at the minute ventilation and its components in COPD
patients compared with normals [23-25], and at the effect of severity of COPD [26] with
different findings which are summarised in table 1.1. The differences in the results have
been attributed mainly to differences in the measuring method.
Sorli et al [23] studied 2 groups of COPD patients, one eucapnic and the other
hypercapnic; and compared their minute ventilation and its components to a normal control
group. Flow was measured using a mouthpiece and Fleisch pneumotach and mouth
occlusion pressure was measured along with the other breathing pattern components. They
found that ventilation was increased in both COPD patient groups compared to the normal
control group but that only in eucapnic COPD patients did this reach significance at the 5%
level. This increase was due to small non-significant changes in frequency and VT.
Tobin et al [24] studied the breathing pattern in normal subjects and in patients
with a variety of disease states using respiratory inductance plethysmography (R.I.P.). In
those with COPD who were not hypercapnic (PaC02 < 44 mmHg) they found that the Vt
and f was moderately increased leading to a raised VE. The Ti was shorter by close to 1
second compared to the normal subjects, the T/Ttot was reduced, and the Vx/^ was
elevated. Findings were similar in COPD subjects who were hypercapnic.
Loveridge et al [25] looked at the breathing pattern of COPD patients compared to
normals using RIP. The patients were categorised as having moderate to severe airflow
obstruction and were all eucapnic. They found that the breathing pattern in the patients
with COPD was significantly different from the age matched normal controls. The rate of
breathing was increased in the COPD group that led to an increase in Vj. Both 4j and TE
were shorter in the COPD group but the VT was unchanged between groups leading to the
Vr/Tj being increased in COPD group. They also found that the variability of these
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Group Ventilation vT Frequency Ti Ti/Ttot Vt/Ti
Sorli [23] t NS NS NS NS
Tobin [24] t T t 4 t
Loveridge
[25, 26]
T NS T 1 NS t
Table 1.1: Change in breathing pattern in eucapnic patients with COPD compared
to that in normal subjects.
(NS = no significant change)
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variables was less in the COPD group. These findings were duplicated in a later paper by
Loveridge [26] in which he compared the breathing pattern in three groups of COPD
patients, a moderate group a severe one and one in respiratory failure, he found no
significant difference between the moderate and severe groups.
Therefore overall the studies show that the minute ventilation in COPD patients is
increased as compared to normal subjects. This is due to small increases in tidal volume and
breathing frequency, which are mainly caused by a decrease in Ti with either no change or a
small decrease in TE. The large changes in T] and small changes in VT means that ventilation
is increased due to an increase in the mean inspiratory flow, and in some cases to mean
expiratory flow.
1.6: Causes of Increased Minute Ventilation in COPD.
The cause of the increase in minute ventilation seen in patients with COPD is not yet
fully understood. There are a number of different processes in the lung, which are affected
by airway obstruction and may play a part in the increase.
1.6.1: Va/Q Mismatch.
In the normal lung there is a distribution of Va/Q ratios due to ventilation changing
less as you go from the apices to the bases than perfusion, as shown by West & Dollery in
1960 [27], In patients with COPD the changes in resistance to airflow and compliance
occur non-uniformly throughout the lung and lead to an increase in the unevenness of
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ventilation within the lungs. Wagner, using the MIGET technique [28], found three distinct
patterns of VA/Q with the lungs of patients with COPD [29] (figure 1.1).
Burrows [30] described two groups of patients with COPD with distinct clinical
presentations. Type A or "pink puffer" have a normal or low PaC02 a mildly decreased
Pa02 and a low carbon dioxide diffusing capacity (TLco) and Krogh coefficient (KCo)-
Type B or "blue bloaters" present with cough and sputum production, fluid retention,
recurrent cor pulmonale, polycythemia and are more likely to be hypoxemic and
hypercapnic.
Wagner also showed that patients with the Type A presentation, mainly had type H
pattern while Type B patients were equally likely to have either type H, L or HL pattern
and mixed Type A and B patients were found to have type H or HL patterns (figure 1.1). It
must be noted however, that an increase in non-uniformity of ventilation may not correlate
to the increase in VA/Q mismatch as the body has a number of mechanisms that tend to
compensate for the mismatch. The first occurs in regions where the VA/Q is decreased, in
these regions perfusion is reduced thereby raising the local VA/Q. West [31] attributes this
to hypoxic pulmonary vasoconstriction (HPV). Von Euler and Liljestrand first described
this in 1946 [32] and a review of the subsequent research into HPV was reported in 1986 by
Voelkel [33]. Kato and Stubbs [34] and Nagasaka [35] have shown that it is the arteries of
the terminal respiratory units in the hypoxic lung region that constrict. However it is not
yet clear whether HPV occurs directly in a localised vascular site with distinct biochemistry
or if it is mediated by a local hormone [33].
The second occurs within the areas of the lung that have a high VA/Q, it is thought
that the fall in PC02 in the airways in these regions causes an increase in their resistance
thereby decreasing ventilation to these regions and reducing the VA/Q [31].
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BLOOD-GAS PARTITION COEFFICIENT VENTILATION-PERFUSION- RATIO
A B
Figure 1.1: Examples of different VA/Q patterns obtained from MIGET [29].
Type H is characterised by a mode of high VA/Q units, type L is characterised by a
mode of low VA/Q and type HL has additional modes both above and below the
main body.
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These disorders of VA/Q matching may lead to increased ventilation in several
ways: -
a) Increased physiological dead space. Areas of high Va/Q will receive ventilation but
not participate in gas exchange. The result will be an effective increase in dead space
ventilation occurring alongside alveolar ventilation, so total Vi will be increased. If
maldistribution of ventilation is sufficiently severe hypercapnia may result, further
stimulating ventilation.
b) Low Va/Q areas classically result in hypoxia, as underventilated units contribute
desaturated blood to the pulmonary veins. If sufficient low Va/Q areas are present
arterial hypoxaemia will result and may stimulate ventilation via the chemoreceptors.
1.6.2: Abnormal afferent traffic from lung receptors.
However there is a group of patients with COPD that do not consistently exhibit
hypoxia, the "pink puffers", and so hypoxia cannot be the only cause for increased
ventilation. A second possible mechanism is abnormal afferent traffic from the lung
sensory and chemoreceptors. In humans regulation of breathing is dependent on a complex
system with three main components. One of these components, the control centre, is acted
upon by afferent neural signals from lung receptors, among other inputs.
Bleecker et al [36] showed that it was the stimulation of the receptors whose
afferent pathways were in the vagus nerves that caused the change in breathing pattern
observed in dogs after inhalation of histamine. This was supported by a study by De Jonste
et al [37] who found that tissue from the lungs of patients with COPD had increased
histamine responsiveness to that from the lungs of patients without COPD. Cazzola et al
[38] showed that pirenzepine (an anti-cholinergic) acted as a bronchodilator in patients with
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COPD by decreasing the sensitivity of the vagal sensory endings and causing a vagal
afferent blockade.
Therefore it can be hypothesised that, in patients with COPD, abnormal afferent
traffic from overly sensitive sensory receptors may act upon the respiratory control centre
via the vagus nerve leading to changes in the ventilatory pattern.
1.6.3: Perception of increased respiratorywork in the chestwall.
A third possible cause of the increased minute ventilation in patients with lung
diseases associated with airflow obstruction is changes in the perception of the respiratory
work of the chest wall. It has been observed that asthmatics tend to overbreathe, Kelsen [39]
observed that it was bronchospasm induced by methacholine inhalation that increased minute
ventilation. They found that the perception of the effort involved in breathing was
heightened and suggested that inputs from the mechanoreceptors in the lungs and greater
stimulation of the chest wall mechanoreceptors as a result of increases in lung elastance may
explain this response.
1.7: Lung Volume and Functional Residual Capacity in Airflow
Obstruction.
In most patients with airflow obstruction FRC and RV are increased, also TLC is
frequently raised especially in those patients with chronic obstruction. Both static and
dynamic mechanisms are involved in the increase in FRC and RV.
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The mechanisms by which FRC is increased are complex and believed to be due to
both the airways' mechanical properties and the control of breathing. One reason is that the
loss in lung recoil pressure results in an increased relaxation volume (Vr) of the lungs (the
volumes at which the lung recoil pressure is balanced by the chest wall recoil pressure).
Another cause is dynamic pulmonary hyperinflation, when FRC occurs above Vr,
due to slowing of expiration to such an extent that expiration is not completed before
inspiration is initiated. The reasons for this slowing of expiration include: -
• The increased resistance to expiratory airflow delaying lung emptying.
• Dynamic collapse of small airways, because of lack of support, causing
dynamic narrowing of the airways and airflow limitation.
These together lead to the inability to increase flow above the prevailing tidal
breathing flow rate (expiratory flow limitation) as described by Pride and Macklem [40].
As airway resistance is lower at higher lung volumes, due to increased lung recoil and
increased radial traction on collapsible airways, patients breathe at higher lung volumes so
that they can increase their expiratory flow rates.
The increase in residual volume (RV) is also thought to be due to a combination of
static and dynamic factors.
The loss of elastic lung recoil results in the airway closure occurring at higher lung
volumes. For the reasons outlined above, expiratory flow is decreased, increasing the time
taken to empty the lungs to such an extent that ERV may be limited by the breath-holding
ability of the patients, also due to lack of support of the airways dynamic airway collapse
may occur at higher lung volumes resulting in gas trapping, with truncation of expiratory
airflow.
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1.8: Respiratory Muscle Activity in Normal Subjects and Patients
with COPD.
The tidal breath flow time curve in normal subjects is sinusoidal in shape with peak
expiratory flow occurring near the middle of the breath. Agostoni [41] hypothesised that
the delay in peak tidal expiratory flow is produced by continued activity of the inspiratory
muscles after the end of inspiration (post inspiratory braking), and that abolition of this
braking would cause a rapid rise in pleural pressure. This was confirmed by studies from
Mcllroy [42] and Pierce [43] who looked at the flow and pressure curves of normal subjects
during voluntarily relaxed expirations.
It has also been shown [44-45] that in patients with COPD the diaphragm is
flattened and its fibres shortened, primarily because of hyperinflation. As a result it
operates at a sub-optimal portion of its length-tension curve and is unable to act as an
effective inspiratory muscle and the transdiaphragmatic pressure generated during
inspiration is less than normal. Brennan et al [46] studied the thoracoabdominal mechanics
during tidal breathing in patients with emphysema while sitting. He found that in most
patients the rib cage motion was greater than in normal subjects, and concluded that the
patients are using their intercostal and accessory muscles during inspiration. They also
observed that some patients had paradoxical inward movement of the lower rib cage during
inspiration (Hoover's sign, believed to result from inward tension exerted by the flattened
diaphragm). The same authors also observed that some patients showed abnormal
abdominal motion with the abdomen diameter being smaller during expiration than during
inspiration at the same lung volume; and concluded that the abdominal muscles were
contributing to expiration. This they suggested could happen in two ways: -
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1. To enable expiration to be completed before an inspiration is triggered.
2. To aid diaphragmatic function by exerting an upward force which will increase
the diaphragm length and curvature before the next inspiration.
Respiratory motion of the rib cage and abdomen in this group of patients is a
complex function of muscle activity, chest wall mechanics and lung mechanics, and apart
from concluding that the diaphragm is disadvantaged during inspiration by the
hyperinflated lungs, fuller understanding of the relative contribution of the accessory
muscles to this movement would require pleural and transdiaphragmatic pressure
measurements supported by EMG recordings and is outwith the scope of this thesis.
A study by Ninane [47] found that the transverse abdominis was the principal
muscle of active expiration and was active before the external oblique and rectus
abdominis. They also found that the expiratory contraction of the transverse abdominis was
significantly correlated with FEV| both expressed as percent predicted and absolute value.
Because the transverse abdominis is a deep muscle, surface electrodes may give a false
negative when trying to detect expiratory muscle activity. Grimby et al [48] have shown
that using abdominal volume, measured by respiratory inductive plethysmography, and
gastric pressure is a more sensitive method of determining expiratory muscle activity.
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1.9: PreviousWork Examining Spontaneous Breathing in Airflow
Obstruction.
The use of tidal breathing flow volume loops (TBFVL) to assess airflow
obstruction when the subject is unable to perform a forced expiration has been examined in
animals and infants.
1.9.1: Animal Studies.
McKiernan et al [49] found that cats suffering from chronic bronchial disease could
be distinguished from healthy cats by a number of variables measured from TBFVL (Table
1.2).
The main differences in the TBFVL were seen during expiration. In the bronchitic
cats peak expiratory flow occurred later in the breath compared to healthy cats,
(approximately end expiration plus 60% of VT in bronchitic cats compared to plus 70% in
healthy ones). Overall the flow volume loop was flatter in the bronchitic cats throughout
expiration with decreased expiratory flows. The timing of the breath was also found to be
different in bronchitic cats with TE being longer than Ti compared to them being the same
in healthy cats.
Petsche et al [50] reported the use of TBFVL in identifying horses with recurrent
airway obstruction (heaves) before it became so severe that clinical signs could identify it.
They found that respiratory frequency was increased primarily due to a shortening in
inspiratory time and an increase in mean inspiratory flow. The pattern of the TBFVL
changed from a biphasic one, to one in which the expiratory peak flow occurred earlier in






Area under the expiratory curve from peak expiratory
flow to end tidal volume (mm2)
3795± 1986 1661 ± 1075
Area under the total expiratory curve (mm2) 5499 ± 2893 3021 ±1736
Volume exhaled 0.5 seconds after the start of a tidal
breathing exhalation (ml)
44.8 ± 12.2 29.5 ±9.0
Peak expiratory flow divided by peak inspiratory flow 1.04 ±0.18 0.78 ±0.10
Expiratory flow at midtidal volume divided by inspiratory
flow at midtidal volume
1.16 ± 0.22 0.82 ±0.10
Expiratory flow at end tidal volume plus 25% VT divided
by inspiratory flow at end tidal volume plus 25% VT
1.06 ± 0.19 0.81 ±0.17
Expiratory flow at end tidal volume plus 25% VT divided
by expiratory flow at end tidal volume plus 12.5% VT
1.27 ±0.09 1.17 ± 0.11
Expiratory time divided by inspiratory time 1.00 ± 0.15 1.31 ±0.14
Inspiratory time divided by total breath time 0.5 ±0.04 0.43 ± 0.03
Peak expiratory flow (ml/sec) 113.7 ±29.1 79.8 ± 19.8
Expiratory flow at end tidal volume plus 25% VT
(ml/sec)
86.32 ±26.5 61.39 ± 21.7
Table 1.2: TBFVL variables which distinguish bronchitic cats from healthy ones [49],
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The difference in where peak expiratory flow (PEF) occurs in cats and horses may
be explained by the fact that in bronchitic cats the TE was increased whereas in horses with
heaves the TE was decreased and it was suggested that increasing the PEF may be the only
way the horses could exhale their VT in the time available. Florses were also observed to
have reduced inspiratory muscle activity during early expiration so that the unopposed
elastic recoil of the lung and thoracic wall causes the high and early peak expiratory flow
rate.
1.9.2: Infant Studies.
Over the last decade two methods have been developed to allow measurement of
forced expiratory flows in infants. However the first, forced deflation technique, requires
endotracheal intubation and the second, rapid thoracoabdominal compression, only
produces a partial expiratory flow-volume loop and it is not known if flow limitation is
achieved used this technique [51 ], therefore studies have been carried out looking at the use
of tidal breathing expiratory flow rate in assessing airflow obstruction by a number of
different groups [52-58]. In the majority of studies the main variables that have been
measured are TPTEf/Te (the ratio of the time needed to reach maximum expiratory flow to
total expiratory time) and dV/VT (the ratio of the volume expired before peak expiratory
flow achieved to expiratory volume).
The results of these studies have been mixed. Carlsen [53] found that both TPTEf/Te
and dV/VT discriminated asthmatic children from healthy ones in terms of baseline values
and reversibility to bronchodilators, whereas both Cutrera et al [52] and Van der Ent [57]
reported that dV/VT and TPtef/Te did not distinguish healthy children from those with
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asthma or cystic fibrosis. However, they both reported that the tidal breathing variables
correlated to maximum expiratory flow volume variables both at baseline and following
bronchodilation or histamine challenge.
However, Aston [54] who studied TPTef/Te during bronchial challenge showed no
change post challenge and concluded that it was an insensitive measure of airflow
obstruction. Clarke [55] also reported that Tptef/Te was an insensitive indicator of airway
obstruction and was only useful in extreme cases when expiratory airflow limitation was
present even during tidal breathing.
Seddon [58] studied intubated and non-intubated premature infants and found that
Tptef/Te correlated to lung compliance but not to airways resistance and concluded that
TPTef/Te maybe influenced by elastic rather than flow-resistive properties.
The difference in the results between the groups could be due to different
methodologies, such as equipment used, i.e. facemask versus mouthpiece, instrumental
dead space; shape of the thorax, position of the subject; state of arousal; post natal age and
the number of breaths sampled and analysed. For example, Cutrera [52] and Van der Ent
[57] recruited school age children (mean age 10.5 yrs. range 5.3 - 17.5 yrs. and mean age 7
yrs. range 3-16 yrs. respectively) studied sitting and awake whereas Aston [54] and Clarke
[55] recruited infants (aged 6-12 months and 1 week to 23 months respectively) studied
supine and sedated. The mechanical properties of the infant chest wall, which is highly
compliant, are known to differ greatly from those found in older children and adults. Van
der Ent [57] stated that further studies are needed to define that possible sources of




In 1981 Morris et al [59] looked at flow against time in normal subjects and
patients with a variety of respiratory disease states. They showed that patients with COPD
did not show the sinusoidal flow pattern observed in normal subjects and patients with
restrictive respiratory diseases but a 3 phase expiratory pattern consisting of i) a rapid rise
to maximum flow, ii) a slow decline in flow throughout most of the expiration and iii) an
abrupt ending of expiration where the flow drops suddenly through zero. Representative
tracings of tidal flow against time in the different patient groups studies are shown below
(figure 1.2). They studied the timing variables derived from the tidal expiratory flow
(which had previous been identified in infant studies i.e. TPTef/Te and dV/VT) to quantify
this difference and found them to correlate with other variables of airflow obstruction.
In 1990 Morris et al [60] studied the causes of the 3 phase expiratory pattern
observed in COPD patients. They observed that the pattern of flow and pressure seen in
these patients with airflow obstruction was the same as that seen by Mcllroy et al [42] and
Pierce [43] in their studies looking at removal of the normal "braking" effect of continued
inspiratory muscle activity in early expiration. This loss of inspiratory muscle braking was
confirmed when they found that inspiratory muscle activity, measured by surface electrodes
at the 7th right intercostal space, stopped abruptly at the end of inspiration (figure 1.3).
They also found that phasic inspiratory activity started just before the flow reversal and
opposed the alveolar pressure (intrinsic peep) still available to drive expiration. The
patients probably sense this as work associated with inspiration and therefore perceive
inspiration as being more difficult.
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Expiration
Figure 1.2: Tracings of tidal flow against time in four patients with airflow
obstruction (upper panel), in three normal subjects (lower panel I,II and III) and one




Figure 1.3: Typical EMG tracings from a normal subject (A) and a representative
patient with chronic airflow obstruction (B)
during tidal breathing showing loss of post inspiratory inspiratory braking. EMG from
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In 1998 two studies by Morris [61] and Williams [62] described three further
variables derived from tidal expiratory flow but this time from the portion of
expiratory flow after peak flow had been achieved. In these cross-sectional studies
they found that these tidal breathing variables correlated with conventional measures
of respiratory function.
Koulouris et al [63] have reported a technique known as negative expiratory
pressure (NEP), which detects expiratory airflow limitation during spontaneous
breathing (figure 1.4). They looked at a group of COPD patients and found that they
could classify the degree of flow limitation depending on whether flow limitation was
present when the patient was supine or when sitting. Eltayare et al [64] have used this
technique to correlate expiratory flow limitation to dyspnoea score.
1.10: Hypothesis.
Since tidal expiration is predominantly a passive event in patients with COPD,
it will be possible to deduce information about the degree of airflow limitation and the
effects of bronchodilators from averaged expiratory tidal flow profiles
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SECTION 2
Chapter 2: Is FEVi the Best Measure of Bronchodilator
Response in Patients with AirflowObstruction?
2.1: Introduction.
As an introduction to the topic of clinical measurements from other than
forced maximal expirations the opportunity arose to study retrospectively a large
number of RVC measurements gathered during routine clinical respiratory function
testing. These data were examined to determine if, during routine spirometry, FEV]
picked up all patients with a reversible component to their airflow obstruction or if
FVC or RVC increased the number of patients termed reversible to bronchodilators.
The hypothesis was that bronchodilators have measurable beneficial effects on
lung function that are not evident on standard FEV] testing. This would lead to
patients who may benefit from bronchodilators being classified inappropriately as non¬
reversible if tested in compliance with current guidelines.
The most commonly used test of respiratory function is forced spirometry,
which was first described as early as 1947 by Tiffeneau and Pinelli [65]. This test is
well understood and the normal ranges for the variables measured are well defined.
However, there are also a number of disadvantages associated with the forced
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expiration. It is unphysiological, (i.e. not a manoeuvre patients perform in everyday
life), shows some effort dependence and only correlates weakly, if at all, with
dyspnoea [4-6], The inspiration to TLC performed prior to the forced expiration can
itself alter the degree of airflow obstruction [8-14],
The 1997 BTS guidelines for the management of chronic obstructive
pulmonary disease [66] stated that when assessing reversibility to bronchodilators the
preferred outcome measure is change in FEV,. Smith et al [7] studied additional
variables in a group of 100 consecutive patients sent for evaluation of reversible
airways obstruction. They measured reversibility in terms of spirometric variables and
plethysmography variables and reported that 82% of patients were identified as
reversible by spirometric variables and 15/18 of the remaining patients were identified
as reversible by plethysmographic variables. They concluded that the patients missed
by spirometry probably had volume related changes to bronchodilators and so a
combination of available tests should be used to test for reversible airflow obstruction.
Plethysmography is however expensive and not universally available.
It has been reported [67] that patients with airflow obstruction often have a
relaxed vital capacity (RVC) which exceeds the forced vital capacity (FVC), the latter




378 randomly selected records from patients who had attended the Respiratory
Function Laboratory at the Western General Hospital, Edinburgh for bronchodilator
reversibility testing between 1993 and 1996 were studied. Randomisation was
achieved by 40 records being picked from each drawer of the filing cabinets holding
the results for these years. Results were included for analysis if the patient had been
referred with a clinical diagnosis of obstructive lung disease, had a baseline FEVi of
less than 80% predicted and a FEVi/FVC ratio of less than 75% and underwent
reversibility testing to either salbutamol or ipratropium bromide. Clinical details on the
request forms indicated that the majority of these patients had a clinical diagnosis of
chronic obstructive pulmonary disease (298/378, 79%), and the majority of the
remainder had a clinical diagnosis of asthma (76/378, 20%).
2.2.2: Data Collection.
Data for FEV), FVC and RVC were available both before and after either 2.5
mg salbutamol and/or 250 pg ipratropium bromide nebulised via a disposable
sidestream nebuliser (Medic-aid Ltd, West Sussex, England) and CR50 compressor
(Medic-aid Ltd, West Sussex, England) in all patients. FEV) and FVC were
performed as per British Thoracic Society (BTS) and Association of Respiratory
Technology and Physiology (ARTP) guidelines [68],
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2.2.3: Measurement of RVC.
RVC is measured as a part of routine spirometry by the pulmonary laboratory
at the Western General Hospital. There is no agreed standard technique for
performing an RVC manoeuvre, patients are simply instructed to "Take a big breath in
and then gently blow all the way out". They start by performing one RVC manoeuvre,
go on to have FEVi/FVC measurements to the standard BTS / ARTP criteria [68] and
then RVC is repeated if 1) RVC was less than FVC, 2) FVC was unobtainable due to
coughing on repeated attempts or 3) FVC had changed more than 10% since a
previous laboratory visit.
2.2.4: Analysis of Data.
The records were analysed to determine those that showed FEVi, FVC and / or
RVC reversibility. Reversibility was defined as 160 ml or greater increase in FEVi
and a 330 ml or greater increase in FVC. RVC reversibility was also taken as an
increase of 330 ml or greater [69],
2.2.5: Statistical Analysis.
To investigate the influence of disease severity on the reversibility
measurements, correlations of reversibility indices with baseline FEVi was performed.
These were evaluated using Pearson's product moment correlation (r) on log-
normalised data. A p value of less than 0.05 was considered significant.
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2.3: Results.
378 patients (201 males) were studied, aged 64 ±12 (mean ± SD) years with
baseline FEVi 57 ± 28% predicted. 48% of patients were treated with nebulised
salbutamol (2.5 mg) only, 4% were given nebulised ipratropium bromide (250 pg) only
and 48% had both. As can be seen from the Venn diagram (Figure 2.5), 48% of this
group of patients had FEVi reversibility and 52% did not. Of those that did not
demonstrate FEVj reversibility 41% could be identified as reversible by FVC or RVC
criteria, 12% by FVC reversibility alone and 12% by RVC reversibility alone.
The correlations between change in the variables following bronchodilator and
baseline FEVi (Figure 2.6) show that, whereas the baseline FEVi did not correlate with
change in FEVi (r = 0.10, p = NS); there was a significant negative correlation between
change in FVC and baseline FEVi 0" = -0.27, p < 0.0001) and change in RVC and
baseline FEVi (r = -0.21, p < 0.0001). This means that patients with a low baseline
FEVi tend to have larger increases in FVC and RVC than those with higher baseline
FEVl's.
298 (166 males) of the patients studied had a referring diagnosis of COPD,
(aged 67 ±10 (mean ± SD) years with baseline FEVi 48 ± 20% predicted). As can be
seen from the Venn diagram (Figure 2.7), 47% of this group of patients had FEVi
reversibility and 53% did not. Of those that did not demonstrate FEV i reversibility 47%
could be identified as reversible by FVC or RVC criteria, 13% by FVC reversibility
alone and 13% by RVC reversibility alone.
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Figure 2.5: Venn diagram representation of results.
Numbers inside circles represent number of patients who demonstrated
reversibility in the variables. Data in brackets represent the percentage of the
total number of patients studied.
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Figure 2.6: Effect of severity of lung disease on reversibility variables.
Correlations of baseline FEVt values with absolute change in respiratory
variables after bronchodilation. Pearson product moment correlation and p
values are shown calculated from log normalised data, N=378.
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Figure 2.7: Venn diagram representation of results for patients with referring
diagnosis of COPD only.
Numbers inside circles represent number of patients who demonstrated
reversibility in the variables. Data in brackets represent the percentage of the
total number of patients studied.
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2.4: Discussion.
This retrospective study of routinely collected lung function data has shown
that 48% of this patient group have demonstrated FEV| reversibility, but an additional
21% had reversibility in RVC and / or FVC but not in FEVi. These FVC and RVC
changes are greater than the within-patient test-to-test variability and therefore
represent physiological change following bronchodilators that is missed if only FEV)
criteria are used.
The BTS guidelines [66] focus entirely on FEVt and state that an increase in
FEVi should be used to define reversibility to bronchodilators and that the post-
bronchodilator FEV, can be used as a marker against which to assess future treatment.
A negative FEVi response does not preclude benefit from bronchodilators in terms of
improved walking distance or a reduction in the perception of breathlessness.
Thus they state, in line with common clinical experience, that some patients
have an unexplained benefit from bronchodilators that is not reflected in FEVi
reversibility. Does this benefit correlate with, and is it predictable from, bronchodilator
changes in FVC and RVC? To answer this would require a prospective study of
subjective and objective benefit from bronchodilators, comparing FEVi responders with
FVC and RVC responders and with non-responders.
One main problem when looking at the response to bronchodilators is the way
in which the change in values is expressed. Anthonisen et al [70] showed that in
patients with COPD the percentage change in FEVi was greatly influenced by the
initial FEVi value. Absolute change was not significantly related to the initial FEVi
although a large absolute change in FEVi was most commonly found in patients with a
high initial FEV,. They concluded that using just one definition of response would
introduce bias and so two variables (absolute change and percentage change) showing
concordant changes should be used to interpret a negative or positive response. Our
data distinguishes responders from non-responders on the basis of absolute change
only, this was chosen as there is no agreed value for a significant increase in FVC and
RVC in terms of percentage change. However when looking at FEVi response alone
for this patient population if significant reversibility was defined as greater than 160
ml and 15% change then a further 40 patients would be deemed unresponsive on FEV)
criteria or if the BTS criteria for expressing significant change in FEVi was used (i.e.
200 ml and 15% increase post bronchodilator) the percentage of patients that would be
defined non-responsive would be increased from 52% to 240/378 (63%). Thus using
either of these alternative definitions of reversibility would result in even fewer
patients being classified as responders despite their showing bronchodilator induced
changes in FVC and RVC greater than the natural variability.
This study also showed a statistically significant negative correlation between
baseline FEVi measurement and the absolute change in FVC and RVC post
bronchodilator. This is not seen with the change in FEVi post bronchodilator. This
means that patients with more severe airflow obstruction are more likely to show
improvement in FVC and RVC following bronchodilators. This may be because
functional effects of bronchodilation are occurring which are only picked up by the
RVC and FVC and remain undetected by FEV). One such bronchodilator effect could
be on the increased closing volume that is often seen in patients with chronic airflow
obstruction. This increase results from a loss in elastic lung recoil and from narrowed
airways and results in an increased residual volume (RV), the amplitude of which is
related to the severity of the lung disease. If after bronchodilation the airway calibre is
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increased, airway closure will occur at a lower lung volume and RV will be decreased.
This would lead to an increase in FVC and RVC that is related to the severity of the
airflow obstruction. However as FEVi is largely unaffected by closing volume these
changes in FVC and RVC may occur in the absence of a change in FEVi.
Another reason for the lack in correlation between baseline FEVi and change
in FEVi may be the way the data are expressed. A study by Brand et al [71 ] examined
the best way of expressing bronchodilator response. They confirmed the conclusions
of Anthonisen [70] that using the percentage change could lead to the belief that
patients with a low initial FEVi were more responsive to bronchodilators. They stated
that if absolute change was used a true bronchodilator response could be distinguished
from random variation in FEVi, but this does not correct for differing lung sizes; such
corrections may be made by relating the absolute change in FEVi to the initial FEVi %
predicted. If this approach is taken with the present study data then the absolute change
in FEVi is still not correlated with the pre FEVi %predicted and the absolute change in
FVC and RVC are still negatively correlated with initial FEVi % predicted (r=0.41
p<0.0001 and r=0.30 p<0.0001 respectively).
This study was retrospective and the following factors should be borne in
mind when interpreting the results. There is no agreed standard technique for
performing an RVC manoeuvre. Attempting to standardise flow rate (for example by
incentive spirometry) was tried but found to be inappropriate because the wide range
of vital capacity in the population results in widely varying expiratory time. Instead
the instruction to patients was simply to "Take a big breath in and the gently blow all
the way out". The range of resulting expiratory flow is therefore large with some
patients, on the first attempt, virtually performing an FVC manoeuvre whilst others
blowing so slowly that the exhaled volume was determined by the breath holding
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ability of the patient. Where these patterns were seen repeat measures were obtained.
Ideally for future studies an optimal standardised method for recording an RVC should
be defined possibly by setting a target flow rate to achieve exhalation of the vital
capacity in a defined time.
The protocol for RVC measurement currently requires a repeat RVC attempt if
the first RVC was less than FVC. While this may have introduced a selection bias
towards finding more RVC > FVC results, it is unlikely that this is an important source
of bias. This is because most measurement errors in FVC and RVC will lead to
underestimation, i.e. it is difficult to get an erroneously high value of RVC or FVC, so
the finding of RVC > FVC, when FVC has been performed to standard criteria of
reproducibility is likely to be a genuine result rather than an artefact ofmeasurement.
In this retrospective study, the precise diagnosis for the patients was not
known, as the investigator was entirely dependent on the clinical details entered by the
requesting physician on the request form. The inclusion criteria were that the patients
were referred with clinical details indicating obstructive lung disease, showed
obstructive spirometry on baseline testing and went on to have bronchodilator
responses tested. The majority had a clinical diagnosis of COPD, many of the
remainder had asthma and a few had miscellaneous diagnoses such as bronchiectasis.
The data for those patients who had a referring diagnosis of COPD only were analysed
and the percentage of non-responders in respective to FEVi only increased by 1% to
53%. All other values were similar to those from the data from all referring diagnoses.
Therefore although each of these diseases leads to airway obstruction via different
processes, as the aim of this retrospective study was to show that in some patients
reversibility to bronchodilators was only shown in vital capacity measurements and not
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in FEVi it was felt acceptable to include all the data regardless of the referring
diagnosis.
Further studies are needed to answer several questions that could not be
addressed by the present retrospective study. Firstly the reproducibility of FVC and
RVC reversibility remains to be determined. Some work has been done studying the
short-term variability of VC by Tweeddale et al [69], They found that an increase of
330ml or more was required to show a significant response in vital capacity to
bronchodilators. This figure excludes the natural variability in the measurement with
95% confidence. However, to date, no studies have been reported which investigate
the reproducibility of the response of FVC and RVC to bronchodilators. Secondly the
correlation of these variables with clinical or symptomatic benefit should be assessed.
The aim of reversibility testing is to target bronchodilator therapy to patients who will
receive clinical benefit from them. The study by Smith et al [7] found that a portion of
patients who showed no FEVi reversibility on spirometry did show significant
improvement in plethysmographic volume related variables, however they did not
measure any score of the patient's subjective breathlessness although this reported
subjective improvement was the basis for their study. The present retrospective study
also involved no subjective measure of clinical improvement.
Therefore, in summary, this study showed that 1) a significant proportion of
this group of patients are being identified as non-responders to bronchodilators on
FEVi criteria when they may, in fact, have measurable physiological improvement
from them; and 2) that FVC and RVC measurements appear to detect a group of
patients who show a functional effect of bronchodilation which is undetectable by
FEV|. This study supports Smith et al's [7] statement that there is no one 'best test'
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for reversibility but that FEV], FVC and RVC should be used together to assess
reversibility especially in those patients with more severe airflow obstruction.
In light of the results from this retrospective study it was felt that alternative
methods of assessing airflow obstruction were needed that would be more sensitive
than FEVi whilst still being easily applicable to everyday clinical testing. The rest of
this thesis examines one possible approach of using tidal breathing expiratory flow
profiles to provide information on the presence and severity of airflow obstruction.
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Chapter 3: Measurement of Tidal Breathing in Man: Methods.
3.1: Determinants of normal tidal flow patterns.
3.1.1: Wakefulness drive.
In 1961 Fink [72] proposed the presence of a wakefulness drive to breathe. In
this study patients were subjected to either passive (mechanical ventilated) or active
(voluntary) hyperventilation so that PaC02 was reduced by at least 10 mmHg and the
Pa02 was raised. It was reported that even though any chemical drive to breathe was
assumed absent the patients who stayed awake all continued to breathe rhythmically at
a normal frequency. However one patient who became drowsy stopped breathing.
Fink therefore asserted that "Cerebral activity associated with wakefulness is a
component of the normal respiratory drive".
This apnoeic response reported by Fink has now been repeatedly observed in
many studies in both anaesthetised and sleeping humans [73-76] made hypocapnic by
either passive mechanical hyperventilation or hypoxia-induced hyperventilation.
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3.2: Critique of Spontaneous Breathing Measurements.
There are a number of problems associated with the use of spontaneous
breathing in the assessment of airflow obstruction. These include: -
3.2.1: Behavioural influences.
As stated above the breathing pattern is influenced by the arterial blood gas
concentrations that change in relation to changing metabolic demands. During
wakefulness the breathing pattern is also influenced by behavioural demands and these
two control systems are in competition with one another.
Shea [77] describes the effects of different behavioural stimuli on the
breathing pattern. He stated that the behavioural control causes inhibitory and/or
excitatory inputs to respiratory motor neurons that affect VT, breathing frequency,
airflow pattern and the recruitment profile of different respiratory muscles.
Behavioural influences include those under explicit voluntary respiratory control e.g.
speech, singing, sniffing or swimming; and those where there is no explicit voluntary
control e.g. mental activity, coughing, swallowing and exercise.
3.2.2: Equipment effects.
Gilbert et al [78] were the first to show that breathing through a mouthpiece,
with noseclips on, into respiratory apparatus results in a higher VT, a lower breathing
frequency and an unchanged or increased minute ventilation compared to unimpeded
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breathing. These changes were attributed to the irritating effects of the instrumentation
on the nasal and oral mucosa. However Douglas et al [79] suggested that the change
in breathing route (i.e. a shift from nasal breathing to oral), rather than the
instrumentation, was responsible for the changes in breathing pattern. This theory was
supported by studies by Rodenstein et al [80]. Perez et al [81] postulated a number of
causes for the change in breathing pattern when using a mouthpiece and noseclip.
These included a change in resistance to airflow, change in dead space, decreased
stimulation of nasal flow receptors and bypassing the humidifying and temperature
adjustment capabilities of the nasal passage. Cole et al [82] observed that the use of a
mouthpiece decreased airflow resistance and stated this could be one reason for the
increase in minute ventilation, this was supported by Weissman et al [83] who found
that decreasing the mouthpiece diameter and thus increasing airflow resistance
prevented the changes in minute ventilation.
Drummond [84] suggested that the use of a mouthpiece and hence oral
breathing was also associated with a smaller FRC and RV than when a mask is used,
possibly via the activation of inspiratory muscles during mask breathing.
3.2.3: Effects of intervention with regard to any changes in FRC
or breathing pattern.
In a study by Rusconi et al [85] the effects of changes in respiratory rate post
histamine challenge on tidal expiratory flow variables in infants were investigated.
They found that the change in Tptef/Te was positively correlated to respiratory rate.
When looked at further they found that with small increases in respiratory rate TE did
not change but Tptef and Tptef/Te did. However in infants who had large changes in
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respiratory rate post histamine, TE was shortened and masked the simultaneous change
in Tptef, such that Tptef/Te did not change. They concluded that Tptef/Te could not be
used reliably to evaluate airways obstruction when concomitant changes in respiratory
rate occurred.
Western and Patrick [86] found that focusing attention on breathing, even
without a facemask or mouthpiece caused the breathing pattern to become significantly
slower and deeper than normal.
It is therefore important to be consistent in the type of measuring apparatus
used when recording tidal breathing in order to decrease any changes in the breathing
pattern due to the apparatus. It is also important to control the external environment so
that stimuli do not affect the breathing pattern during recording of tidal breathing.
Ingvar [87] and Phelps [88] defined a "resting unstimulated state" for their studies.
They stated that the subject should be relaxed with a minimum of sensory input motor
output and cognitive activity whilst avoiding fluctuations in the level of alertness.
Shea et al [77] found that this was impossible to achieve in most people for long
periods without causing drowsiness. For studies lasting longer than about 10 minutes
Shea aimed at making measurements in a steady state, with the subject reading or
listening to a taped story in order to control the level of arousal.
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3.3: Collection of Tidal Breathing Data.
3.3.1: Introduction.
The studies described in the following chapters rely upon the reproducible
collection of tidal breathing data during a steady resting state. Consideration of the
points outlined below was important whilst developing the collection methodology.
• Auditory and visual stimuli.
• Effect of differing levels of arousal.
• Equipment effects.
The collection method has evolved over time and only the final protocol is
described here.
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3.3.2: Choice of Equipment.
3.3.2.1: Flowmeter.
Accurate flow measurements are central to the examination of tidal flow
patterns, it was therefore important that the flowmeter used fitted the following
criteria: -
• Light weight. As the flowmeter would be attached to the subject via a
facemask with no other support it was important that it was as light as
possible to avoid discomfort to the subject.
• Add minimal external resistance. In order that the effects of the measuring
equipment on the breathing pattern be minimised as much as possible it is
important that the flowmeter should not add an external resistance. ATS
criteria [89] are that the resistance should be less than 1.5 cm H20/L/s.
• Minimal dead space. Sackner et al [90] reported that increasing the dead
space of the recording equipment increased ventilation by increasing VT,
therefore to minimise equipment effects, the dead space of the flowmeter
should be as small as possible.
• Linear response over the physiological range of resting flows.
• Stable zero flow over long periods of time.
The flowmeter used throughout this work is the Birmingham Research and
Development Limited (BRDL) ultrasonic flowmeter, which has the following
specifications: -
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• Weight 100 g.
• Linearity, quoted by manufacturer as linear over 60 L/sec, tested over a
range of flows from -2 L/sec to 2 L/sec (see chapter 3.3.2).
• Acceptably low dead space (175ml).
• Minimal resistance to airflow.
• Stable zero over time periods of at least 20 minutes. Not adversely
affected by condensation, as zero flow does not drift after it has been
breathed through for at least 20 minutes (see Appendix C).
For a detailed explanation of the principle of operation and technical
specifications see Appendix A.
3.3.2.2: Face mask.
Studies [78-83] have shown that breathing through a mouthpiece increases Vx
and VE and may lower frequency. Later studies [79-81] have suggested that this
change is due to the change in breathing route from nasal to oral, rather than the actual
instrumentation. Drummond [84] has also shown that FRC and RV are reduced during
mouthpiece breathing compared to mask breathing. To overcome this effect on
breathing pattern we used a face mask during tidal breathing flow collection, so that
each subject could breathe through their nose, mouth or a combination of the two,
thereby not altering their normal breathing route. The self-sealing adult facemask
(System 22, Medic-Aid Ltd, West Sussex, England) used has an inflatable balloon seal
and is lightweight, 50 g (figure 3.8).
During the studies it is necessary to change from recording flow to delivering
inhaled therapy. Removal of the facemask flow meter assembly to allow therapy to be
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Figure3.8:Photographsft emodifiedfacaskusd lbre thingl wdatrecordinl nwittt c dsides eam nebuliserandultrasonicflowmeter.
given would cause disturbance to the subject and necessitate a second acclimatisation
period. To overcome this a second port was added to allow the flow meter and a
nebuliser pot to be attached concurrently (figure 3.8). The disadvantage of this
arrangement is that the dead space of the equipment was increased from 175 ml to 215
ml (the equipment dead space of the mask was measured by fitting it to a simple model
of a face and filling with water, the dead space of the nebuliser chamber was also
measured by water fill). However the advantage of not needing to disturb the subject
outweighs this increase in equipment dead space.
3.3.2.3: Computer.
To facilitate averaging and analysis, data were captured directly to a computer
and stored in digital form. The output from the flow channel of the flowmeter box was
connected to channel one of an Amplicon PC26AT analogue to digital converter, via a
connector box. An in-house computer program (Appendix B) sampled the flow data
from the ADC card at 100 Hz. This frequency was chosen, as it is sufficiently high to
reproduce the frequency content of the physiological flow signal. The data were
converted into mV, using a computer algorithm, and then into L/sec and the result
stored on disk. The mV to L/sec conversion factor was calculated by using a rotameter
to blow air through the flowmeter at known flow rates (see section 3.3.2).
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3.3.3: Control of visual and auditory stimuli.
3.3.3.1: Blindfold.
In 1996 Shea et al [91] reported the effects of visual and auditory stimuli on
resting ventilation. They found that adding either auditory or visual stimuli to a
baseline condition of relaxed wakefulness increased VE, and decreased frequency and
concluded that when measurements of breathing at rest are made the environmental
and behavioural variables need to be controlled. To achieve this all studies were
carried out in a quiet dimmed room with the subjects blindfolded.
3.3.3.2: Tape player and headphones.
Ingvar [87] and Phelps [88] have defined a 'resting unstimulated state' for
making respiratory measurements, stating that the subjects should be relaxed with a
minimum of sensory input, motor output and cognitive activity. However due to the
length of time that subjects' breathing was recorded (between 15 and 40 minutes), it
was possible that subjects would become drowsy or even fall asleep, as a result of
controlling the environmental and behavioural conditions, thereby changing the
"wakefulness drive to breathe" [77] component of their breathing pattern throughout
the study. Studies were therefore performed under conditions of resting steady state as
outlined by Shea [77] by playing the subjects a taped story through headphones to
control the level of arousal. This had the added benefit of providing a distraction to
the subjects so that they did not think about their breathing and change their breathing
pattern.
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Patients were observed during the recording periods for any evidence that they
had fallen asleep, such as loss of small body movements or slowing of the respiratory
rate. They were also required to perform maximum inspiration at 5 minute intervals
during the recording periods allowing the level of wakefulness to be assessed and
asked at the end of the recording period if they had fallen asleep.
3.3.4: Protocol.
Subjects for all studies described in this thesis were recruited from the
population of patients who attended the respiratory function laboratory for routine
reversibility testing. They were told that the purpose of the studies was to look at
different ways of assessing breathing problems, but were not told that it was tidal
breathing that was being primarily studied.
Chairman's approval from the local Ethics Committee was obtained prior to
commencement of the studies and informed consent was obtained, in writing, from
subjects at the time of their enrolment into the studies.
Subjects were fitted with the self-sealing facemask with a rubber head strap
and the mask checked for leaks. The ultrasonic flowmeter was connected to the top
port on the facemask and the nebuliser pot attached, via an angled connector, to the
lower port (figure 3.8).
Subjects were asked to sit on a couch in a semi recumbent position with their
head resting on a pillow, so that they were as comfortable as possible and asked not to
move or speak during the study period, so that breathing artefacts were not introduced,












Flow rate was sampled by the PC at 100 Hz.
Figure 3.9: Diagrammatic representation of flow recording and nebulisationequipment.
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salbutamol reduces dynamic hyperinflation therefore to monitor the lung volume at
which subjects were breathing, the inspiratory capacity (IC) was measured. Subjects
were told that they would be asked to breathe in until their lungs are full and then hold
their breath for 1-2 seconds approximately every 5 minutes. The breath hold period
also allowed monitoring of zero flow to ensure no drift had occurred during the study
period. They were not told that their spontaneous breathing pattern was being
recorded, again to limit how much they thought about their breathing.
The subject was left for at least 5 minutes to rest and then once the equipment
was attached and the subject was comfortable they were left for a further 2 minute
acclimatisation period so that they had time to get used to breathing with the facemask
on and to relax so that a steady state was achieved. These times were judged adequate
after analysis of much longer periods of tidal breathing under these circumstances in
pilot studies (see chapter 3.3.1). No subjects were unable to tolerate the recording
equipment and none admitted to falling asleep on questioning after the study.
After this time for acclimatisation, sampling of airflow was started and once
every 5 minutes the subject was asked to inhale to total lung capacity and then breath-
hold for 2-3 seconds at TLC.
If nebulised treatment was being given, flow sampling was stopped and a three
way tap (placed between the compressor and the inlet of the nebuliser pot) opened to
connect the compressor to the nebuliser pot and allow nebulisation to begin.
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3.4: Analyses Of Tidal Breathing Data.
3.4.1: Introduction.
In house computer programs were developed for the analysis of the flow data.
This allowed for fast analysis of a large number of breaths, which would have been
impossible if the analysis was done by hand.
There were a number of problems associated with the recording of tidal
breathing and its analysis that had to be overcome. The main one was the breath-to-
breath variability observed during spontaneous tidal breathing. Priban [15] observed
that there were breath-to-breath variations in the rate and depth of spontaneous
breathing pattern in normal subjects. Newsom Davis [17] looked at volume and time
components of breathing pattern and again found breath-to-breath variability in normal
subjects at rest. Loveridge [25] studied the spontaneous breathing pattern at rest in
subjects with chronic airflow obstruction and observed that although the breath-to-
breath variability was less than in normal subjects it was still present. Therefore if
only one or a few breaths were analysed per subject per study period any change
observed could be due to breath-to-breath variability and not a true change.
To overcome the problem of breath-to-breath variability it was decided to
sample and record 5 minutes of tidal breathing for each set of data required. This
equated to 13 ± 5 breaths per minute. From this large number of breaths average
breaths were calculated for each study period that could be compared before and after
treatment and with conventional respiratory variables. The creation of averaged breath
profiles results in very significant reduction in the random and cardiac-related flow
artefacts seen in single-breath recordings. However there were still a number of
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problems inherent in calculating an average breath from a large number of variable
breaths. These included: -
• Aberrant breaths due to body movement or behavioural influences under
explicit voluntary respiratory control e.g. speech, sniffing and sighing; and
those not under explicit voluntary control e.g. coughing and swallowing.
• Varying breath length. As stated above breath length can vary breath-to-
breath meaning that averaging is not a simple as it first appears.
Various steps in the calculation of averaged breaths were performed to
overcome these problems. As with the collection protocol the analysis procedure has
evolved and only the final analysis method is outlined here. A copy of the program
can be found in Appendix B.
3.4.2: Tidal Breathing Analysis Program.
Each period of breathing was checked for zero flow drift, and re-zeroed if
necessary (figure 3.10). Algorithms were then applied to determine the start of each
expiration and inspiration and, in order to exclude expiratory pauses, the end of
expiration (figure 3.10). These algorithms were developed by visual inspection of
large amounts of raw flow data to determine the equations which best picked up the
start of expiration and inspiration. The end of expiration was defined as the point at
which the flow rate falls below a threshold value of 5 ml/sec (see Appendix B).
Raw flow data were displayed visually, on the computer screen, as a flow /
time graph along with the automatically generated breath markers. A dialog box was
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Figure 3.10: Screen shot of tidal breathing analysis program showing A) re-
zeroing of flow and B) sample flow data with breath markers inserted.
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then activated which allowed the operator to select breaths for analysis. All available
breaths were included with the following exceptions: -
• Aberrant breaths due to sighing, coughing, speaking or swallowing were
visually identified and manually excluded from further analysis along with
one breath either side.
• Breaths that had not been detected by the breath detection algorithms.
• Exceptionally long or short duration breaths (see below).
Because of the way that the averaging is performed for subsequent analysis
(see above) any abnormally short or long breaths would affect the average breath.
Including short breaths would mean that the average breath would be short, as
averaging is stopped when the end of the shortest breath is reached. Similarly,
including very long breath in the averaging would mean that the averaged breath
would include data from only the first portion of a long breath and therefore artificially
increase the flow rate of the later part of the averaged breath. Therefore the analysis
program excluded any abnormally short or long breaths from the averaging, to do this
the mean breath duration (MBD) of the selected breaths was calculated and any
breaths outside of ± 15% of the MBD were excluded. The value of 15% was
determined by looking at frequency histograms of expiratory time for 5 minutes of
tidal breathing data for 4 subjects and determining the percentage ofMBD that would
exclude "outsider" breaths (figure 3.11).
The remaining breaths were then used to calculate the standard tidal breathing
variables as summarised in table 3.3. The novel tidal breathing variables were
calculated from averaged breath data. Because of variable breath lengths a simple
average breath for a complete inspiration and expiration could not be produced.
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Figure 3.11: Data from two representative patients
showing the number of breaths to be excluded if those outside of the mean
breath duration (MBD) ± 15% were omitted from analysis.
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Variable Units Description
VT L Tidal volume
F Bpm Frequency
VE L/min Minute ventilation
Te Sec Expiratory time
Ti Sec Inspiratory time
Tet Sec Expiratory time to flow threshold (excluding
expiratory pauses)
Ttot Sec Total breath duration
Table 3.3: Conventional tidal breathing variables calculated from raw tidal flow
data.
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There were a number of possible ways to overcome the problem of varying
breath duration. Benchetrit [21] and Williams [62] et al used a method of normalising
the breath duration. However as the mechanical relaxation properties of lung tissue are
time-dependent, normalising breath length would arbitrarily distort the data in the time
dimension, potentially obscuring important but small changes in the flow pattern.
Therefore two different averaged breaths were produced for each time period (figure
3.12). The first, to examine the early part of the expiratory flow profile, was created by
breaths being aligned at the onset of expiration and averaged up to the end of the
shortest breath (SExp). The second, to examine late expiration, was created by breaths
being aligned at end expiration and averaged back to the onset of the shortest breath
(Eexp)- For each method, flow data were averaged in 10ms time bins. A number of
variables could then be measured from these "bin-averaged" breaths.
A summary of the different methods that could be used to generate
representative tidal flow profiles along with advantages and disadvantages of each
method is shown in table 3.4
3.5: Validation of Data Collection Protocol.
3.5.1: Optimisation of the data collection time.
3.5.1.1: Introduction.
Not only must any new test of airflow obstruction be reliable and reproducible it
must also be acceptable to the patients to perform. During the collection of tidal
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Time (sec) Time {sec)
Figure 3.12: Diagrammatic representation of time bin averaging used to
construct average breaths from tidal breathing flow data.
(a) To examine the early part of the flow profile, breaths were aligned at the
onset of expiration and averaged up to the end of the shortest breath, (b) To
examine late expiration breaths were aligned at end expiration and averaged






No distortion of data Extremely laborious therefore
limited to only a few
(?representative) breaths







One way to overcome
differing breath length
Distorts data in time dimension,
affecting time-dependent relaxation
data
Each breath needs separately







Easily automated for large
numbers of breaths
No distortion of flow data in
the time dimension
Cannot generate a single complete
averaged breath (but can still
compute mean Ti, Te and Ttot)
Table 3.4: Summary: methods of generating averaged "representative" tidal
flow profiles
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breathing data the most common comment from subjects was that it took a long time
and that wearing the face mask could get slightly claustrophobic towards the end of the
collection period. Also the longer the collection time the larger the probability that the
patient would become drowsy and any change in wakefulness could cause breathing
pattern changes as discussed earlier. In pilot studies, 15 minutes of resting tidal data
were collected and this made possible the comparison of values obtained from the first
5 minutes of data with those obtained from the full 15 minutes of data. This analysis
was performed to determine the minimum time needed for collection of acceptable
data.
3.5.1.2: Method.
Data collected from pilot studies were analysed. Briefly, the subjects were
allowed to relax for at least 5 minutes whilst the equipment was prepared. Then to
allow them to acclimatise to the flow recording equipment they were left for a further
2 minutes, once the equipment was attached (as described in chapter 3.1.4), before
airflow sampling and recording was started. 15 minutes of airflow data from
spontaneous tidal breathing were then sampled, displayed and stored on computer.
The 15 minutes of data were divided into 3 sets of 5 minutes and average
breaths and tidal breathing variables calculated on both the full 15 minutes of data and
on the first 5 minutes of data. Paired t-tests were performed to determine if there were
any significant differences between the results obtained from 5 and 15 minutes periods
of data.




Data were collected from 25 patients (4 studies per patients). There were no
significant differences between the tidal breathing variables obtained from 5 minutes of
data compared with those obtained from 15 minutes of data (Table 3.5) Bland and
Altman plots [93] were constructed for VT. Freq, Ve, EF25, TBEV) and TPEF showing
the results graphically (figure 3.13), and these confirm that there is no systematic
difference between the results obtained by collecting 5 minutes and 15 minutes of data.
3.5.1.4: Discussion.
In order to optimise the methodology for patient compliance and acceptability
and to make the test applicable for every-day use it was necessary to decrease the
collection time. A sampling period of 5 minutes was used because at a normal
breathing frequency of 12 breaths per minute this gave approximately 60 breaths to be
used in the construction of the averaged breaths. This could only be done if the results
calculated from the 5 minutes of data were not significantly different from that
obtained from the original 15 minutes of data. An analysis of data has shown that
there were no statistically significant differences between the two collection times for
any of the tidal breathing variables, whether calculated from the original data (e.g. VT,
freq and VE) or calculated from the averaged breaths (e.g. EF25, TBEVi and TPEF (see
chapter 5.1). Therefore all subsequent study protocols involved data collection over 5
minutes instead of 15 minutes.
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Variables Median value Significance
15 minutes 5 minutes
VT 0.63 0.63 NS
Freq 17.0 17.2 NS
VE 10.5 10.6 NS
te 2.22 2.21 NS
Ti 1.33 1.30 NS
Tet 2.22 2.20 NS
Ttot 3.52 3.47 NS
ef25 0.25 0.25 NS
tbev, 0.37 0.37 NS
tpef 0.49 0.49 NS
Table 3.5: Comparison of values calculated from 5 and 15 minutes worth of
data.
P values from Wilcoxon Signed Rank Test. NS = not significant.
81
0.0 0.5 1.0 1.5 2.0 2.5
m
-20-] T T 1-
0 10 20 30
mean of 5 & 15 mins values mean of 5 & 15 mins values
Figure 3.13: Bland and Altman plots showing comparison of 5 and 15 minutes
data analysis.
Solid line is the mean difference and dashed lines the 95% confidence limits of
the difference between results from 5 and 15 minutes data.
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3.5.2: Verifying the sampling rate and Determining the flow rate
correction factor.
3.5.2.1: Introduction.
Before the data collection protocol could be used in any study, the sample rate
had to be checked to ensure that it was 100 Hz. Also the correction factor had to be
determined to convert the voltage output from the analogue to digital converter to L/sec
for the flow rate channel.
3.5.2.2: Method.
To check the sampling frequency a signal generator was connected to the flow
rate channel of the connector box. This was then used to deliver a square wave pulse at
three different frequencies (10 Hz, 1 Hz and 0.1 Hz).
The voltage output from the signal generator was recorded using the data
collection programme and the data subsequently analysed to check that the collection
programme was sampling at 100 Hz.
To calculate the correction factor for the flow rate a rotameter was connected to
ultrasonic flowmeter and flow was recorded at a range of rates between -2 L/sec and 2
L/sec. The resulting voltage output from the ADC recorded at each flow rate were
plotted against the flow rate and linear regression used to calculate a conversion
equation.
Once the correction factor had been determined, it was checked by putting 3
litres of air through the flowmeter at different stroke rates using a Hans Rudolph
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calibrating syringe. The resulting volumes calculated from delivering 3L at differing
flow rates were recorded and the variability calculated.
3.5.2.3: Results.
The number of samples in each square wave was counted for each of the three
frequencies. Figure 3.14 shows that for 10 Hz each square wave consisted of 10
samples, for 1 Hz each square wave consisted of 100 samples and for 0.1 Hz each
square wave consisted of 1000 samples. This confirmed that the programme was
sampling at 100 Hz, i.e. 100 samples every second.
Figure 3.15 shows the raw data recorded by the data collection programme at
the different flow rates applied to the ultrasonic flowmeter by the rotameter.
Figure 3.16 shows the linear relationship between the voltage output from the
ADC and the actual flow rate. The equation of the fitted line was hard coded into the
analysis program so that all resulting flow data were recorded in L/sec.
Regression line equation
Flow (L/sec) = 0.00529 + (0.00486 x ADC voltage (mV))
3L Syringe Calibration
Table 3.6 shows that the average volume measured was 3.03 litres. This is
within 1% of the actual volume of 3.00 litres that is within the ATS guidelines for















Figure 3.14: Output from ADC from application of square wave pulses
at 10, 1 and 0.1 Hz showing number of samples per pulse.
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Figure 3.15: Raw data voltage output from ADC at a range of flow rates























Figure 3.16: Scatter plot of actual flow rate and recorded voltage output from
the ADC along with the fitted linear regression line and regression equation.
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Stroke Speed Fast Medium Slow










Mean (L) 3.03 3.02 3.04
SD 0.06 0.08 0.05
Table 3.6: Volumes recorded from multiple strokes of a 3.00 L calibrating
syringe at 3 different stroke speeds.
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3.5.2.4: Conclusion.
These data confirm that the apparatus had the necessary accuracy, linearity and
frequency response required for the intended range of physiological measurements.
3.6: Conventional respiratory function variables.
3.6.1: Introduction.
Conventional respiratory function variables were measured to allow
comparison of the tidal breathing variables. There is no agreed gold standard for
measuring airflow obstruction; we therefore recorded both spirometry (FEVi and
FVC), which are the most commonly used tests and airways resistance that a number
of groups believe to be the gold standard. Lung volumes were measured to monitor the
level ofFRC.
3.6.2: Spirometry.
Spirometry was performed using either a Fleisch pneumotach as part of the
Jaeger whole body plethysmograph or a Vitalograph wedge bellows spirometer. Both
pieces of equipment are routinely used within the pulmonary function department for
spirometry and were calibrated each study day by J. Montgomery and quality
controlled weekly by a qualified respiratory function technician. The plethysmograph
was also calibrated before each study using the equipment's standard calibration
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program. Forced expiratory manoeuvres were performed to BTS and ARTP standards
until 3 technically satisfactory results were achieved. Relaxed vital capacity was also
measured on all patients (see chapter 2.2.3).
3.6.3: Airways resistance and Lung Volumes.
This was measured by the Jaeger whole body plethysmograph using a
modification of the DuBois method [94], As the plethysmograph software corrected
for changes in temperature and humidity within the box, measurements of airways
resistance (Raw) and thoracic gas volume (Vtg) could be made from tidal breathing
without the patient having to pant. Airways resistance was calculated from pressure
volume loops and Vtg calculated from pressure volume loops recorded during periods
of no flow (respiratory effort against a closed shutter) and sGaw calculated from the
Raw and Vtg. Subjects then performed a slow vital capacity manoeuvre to allow other
lung capacities and volumes to be calculated. All measurements were made to BTS
and ARTP standards [68] and three technically satisfactory sets of results with less
than 10% variation in total lung capacity (TLC) were obtained for each measurement.
3.7: Statistical Analysis.
All statistical analysis of the results was carried out using commercially
available software (SigmaStat for Windows V 1.0, Jandel Corporation) on a personal
computer. Data were tested for normality and then where appropriate parametric or
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non-parametric statistical methods applied. Results were considered to be statistically
significant if the probability was < 0.05.
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SECTION 3
Chapter 4: Measurement of Tidal Breathing: Outline of
Studies.
The following outlines the programme of studies undertaken to investigate the
usefulness of variables measured from tidal breathing expiratory flow profiles in
assessing airflow obstruction. Each study was set up to examine a different set of
questions.
Many variables can be derived from the expiratory flow profile. The
following questions were therefore asked:
• What variables can be measured and used in the assessment of airflow obstruction
(Section 5.1)?
• How do tidal variables correlate with conventional variables between subjects
(section5.2 & 5.3)?
• What is the measure-to-measure variability of the novel tidal breathing variables
and the conventional variables (Chapter 6)
• How reproducible were the baseline values in the short and long term (chapter 1)1
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• How reproducible were the responses in tidal breathing variables following
bronchodilation in the short and long term (chapter 7)?
• How does the change in tidal variables and conventional variables correlate with
subjective changes in breathlessness following bronchodilation (chapter 8)?
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Chapter 5: Defining and Validating Tidal Breathing Variables in
Patients with COPD.
5.1: Introduction.
Once the protocols for the collection of tidal breathing flow data and for the
average breath calculation had been finalised it was necessary to identify variables
measured from the averaged breath that reflected airflow obstruction. There were two
sources for these novel variables (table 5.7).
5.1.1: Existing Variables.
Tidal breathing has been studied as a way of identifying airflow obstruction in
animals [49,50], infants [51-58] and adults [59-64], and a number of variables of
obstruction have been identified.
The variables chosen to be investigated using data collected as described in
chapter 3 were those that could be measured directly from the flow data. They
consisted of standard descriptors of breathing pattern (VT, TE and T|), other time
components of tidal breathing (TTOt and Te/Ti) and flow related variables (PEF/PIF,
EF25, dV/VT, Tptef and TpjEf/Te).
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5.1.2: New self developed variables.
From review of the literature, the following hypothesis was formed. Since tidal
expiration is predominantly a passive event in patients with COPD, it will be possible
to deduce information about the degree of airflow limitation and the effects of
bronchodilators from averaged expiratory tidal flow profiles. This implies that the
initial phase of expiratory tidal flow will be determined principally by elastic recoil
and the degree of airflow obstruction. Therefore if airflow obstruction is reduced,
following bronchodilation, the flow rates and volume expired at the start of expiration
should increase.
Variables were therefore sought which should be sensitive to this increase in
flow rate. As the time course of any changes was not known data were examined from
both the beginning and the end of the expiration. A number of variables were tested:
TBEV0.5, TBEVi and TBEV2 (the volume of air exhaled in the first half a second,
second and two seconds of a tidal breath), TPEF (the peak tidal expiratory flow rate)
and TEEV i (the volume of air exhaled in the last second of a tidal breath, excluding
any expiratory pause).
5.1.3: Variables selected for study.
Pilot studies were carried out in 17 patients with COPD to determine which of
the variables detailed above might be sensitive indicators of changes in airflow
obstruction following a therapeutic dose of salbutamol. Those variables that changed
most, and most consistently, in a biologically plausible direction were then selected for





EF25 Expiratory flow at end tidal volume plus 25% end tidal
volume [50].
TpTEF Time to peak expiratory flow
Tptef/Te Time to peak expiratory flow / expiratory time [59],
Novel
TBEV-i The volume of air exhaled in the first second of a tidal
breath.
TPEF The peak tidal expiratory flow rate.
TEEV-i The volume of air exhaled in the last second of a tidal
breath, (excluding any expiratory pause).








Figure 5.18: Diagrammatic representation of self developed tidal breathing
variables.
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figures 5.17 and 5.18. The remaining variables, listed in table 5.8, were excluded from
further study.
This approach was chosen in an attempt to minimise the effect of mechanistic
preconceptions on the choice of new measures.
In order to examine the usefulness of each of these variables in assessing the
degree of airflow obstruction present it was necessary to obtain values of the tidal
breathing variables at various levels of airflow obstruction. One possible approach for
this would be to look at a large number of subjects with varying degrees of airflow
obstruction, however this approach introduces between subject variability into the
analysis. An alternative approach was therefore chosen; of looking at a smaller number
of subjects with variable airflow obstruction studied at different levels of severity so
that each subject acted as their own control. To achieve the different levels of airflow
obstruction subjects were studied after they had withheld their bronchodilators and after
bronchodilation, in order to confirm that any effects where due to the bronchodilation







Ttot Total breath duration
Te/T, Ratio of expiratory time to inspiratory time
PEF/PIF Ratio of peak expiratory to peak inspiratory flow rate
DvA/T Ratio of the volume expired before peak expiratory flow
achieved to expiratory volume
Novel
TBEV0.5 The volume of air exhaled in the first half second of a tidal
breath.
tbev2 The volume of air exhaled in the first two seconds of a tidal
breath.





28 patients (21 males), with a diagnosis of COPD, were studied on two
different occasions with different treatments (random order blinded to subject and
investigator). The mean (SD) age of the patients was 63 (11) years; they had mild to
severe airflow obstruction (45.0% (20.8%) mean (SD) FEVi %predicted) and
previously demonstrated partial reversibility to salbutamol and/or ipratropium bromide
(> 160ml increase in FEVi post [86]). A further 21 patients were studied on a single
occasion with active treatment. The mean (SD) age of these patients was 70 (7) and
they had similar severity of disease as the previous group (43.0% (15.5%) mean (SD)
FEVi %predicted) and had also previously demonstrated partial reversibility to
salbutamol and/or ipratropium bromide. Patients were recruited from the population
who had attended the pulmonary function laboratory for reversibility testing within the
past 4 years.
Subjects were requested to withhold their short acting bronchodilators for 4
hours prior to testing on the 2 study days.
All subjects were free from upper or lower respiratory tract infections for at
least 2 weeks prior to the study.
Written informed consent was obtained from each patient prior to
commencement of the study.
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5.2.2: Protocol.
The equipment and experimental set up are described in detail in chapter 3.1.1
and 3.1.2.
The time line diagram (figure 5.19) shows the sequence of tests and study
medication. Briefly, spirometry and plethysmography were performed according to
BTS and ARTP guidelines [68], To allow the subjects time to settle they were allowed
to relax for at least 5 minutes whilst the equipment was prepared. Then to allow them
to acclimatise to the flow recording equipment they were left for a further 2 minutes,
once the equipment was attached, before airflow sampling and recording was started.
5 minutes of airflow data from spontaneous tidal breathing were then sampled,
displayed and stored on computer. Without disturbing the patient or mask in any way
the mask-mounted nebuliser (sidestream nebuliser and CR50 compressor, Medic-Aid,
West Sussex, England.) was activated to deliver the study medication. A further 5
minutes of tidal breathing flow data were then sampled, displayed and stored and then
spirometry and plethysmography repeated.
Twenty eight patients performed two separate studies on different days. On
one occasion they received 2.5 mg of salbutamol and 250 pg of ipratropium bromide
by nebuliser and on the other nebulised normal saline. The order was randomised and
both the patient and investigator were blinded to the order of the medication, as an
independent member of the Respiratory Function Laboratory staff loaded the













Figure5.19:Timlineofthseq nceesti gfainglt dyd y. key
13technicallysatisfactorFEV!,VC(R w05,V ginub et). L15mins.spontaneoustid lbreathingwithainspira i nTLCd2-3econdre th-holv ry5i 3 nebulised2.5mgsal utamol±50pipratropiub omide,rlinpl ceb(ra dordert yd ys).
of salbutamol and 250 |Lig of ipratropium bromide by nebuliser, with no placebo
(saline) limb.
5.3: Results.
5.3.1: Correlation of tidal variables with conventional variables of
airflow obstruction.
There were significant positive linear relationships between FEV| and TBEVi
(r = 0.33, p = 0.02) and EF25 (r = 0.40, p = 0.004). TPEF was not significantly
correlated with FEVi. There were significant linear relationships between sGaw and
TBEVi (r = 0.46, p = 0.003), TPEF (r = 0.35, p = 0.03) and EF25 (r = 0.40, p = 0.01)
(figure 5.20). Thus patients with worse airway obstruction as measured by
conventional variables had lower values for TBEVi, TPEF and EF25 and the
correlations were generally stronger for sGaw than with FEV].
5.3.2: Effect of bronchodilation.
Mean (SD) values pre and post treatment in the active and placebo groups are
presented in tables 5.9 and 5.10 for both conventional and novel tidal breathing
variables. The values pre treatment were compared with those post (table 5.9, 5.10,
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Figure 5.20: Correlation of baseline tidal breathing variables (TBENA,, TPEF
and EF25) with baseline A) FENA (n = 49) and B) sGaw (n = 39).
Pearson's product moment correlation (r) and p values are shown.
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VARIABLE (units) Abbrev" Active treatment
Pre Post P value
Forced expired volume in lsec (L) FEV, 1.33 (0.66) 1.62 (0.68) <0.05
Forced vital capacity (L) FVC 2.63 (0.89) 3.31 (0.95) <0.05








Residual volume (L) RV 3.91 (1.32) 3.49(1.22) <0.05





Minute ventilation (L/min) VE 9.6(1.66) 11.1 (1.87) <0.05










Mean inspiratory flow rate Vt/T, 0.41 (0.10) 0.52 (0.12) <0.05





Ratio of Tptef to exp. time Tptef/Te 0.16(0.08) 0.14(0.09) NS
Flow at 75% of tidal volume (L/s) ef25 0.24 (0.05) 0.28 (0.06) <0.05
Volume expired in last sec. Of tidal
breath (L)
TEEV, 0.16(0.06) 0.18(0.06) NS
Volume expired in first sec. of tidal
breath (L)
TBEV, 0.35 (0.08) 0.41 (0.10) <0.05
Tidal peak expiratory flow rate (L/s) TPEF 0.48 (0.12) 0.56(0.14) <0.05
Inspiratory capacity (L) IC 2.80 (0.83) 2.84 (0.82) NS
Table 5.9: Conventional and tidal breathing variables. Mean (SD) (or Median
(interquartile range) for those data not normally distributed) values for
spirometry, whole body plethysmography and tidal breathing variables pre and
post active treatment.
Pre treatment values compared with post treatment values by 2 way RM
ANOVA with pairwise comparisons using Student-Newman-Keuls test.
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Variable (units) Abbrev" Placebo
Pre Post P value
Forced expired volume in 1 sec (L) FEV, 1.29 (0.75) 1.32(0.77) NS
Forced vital capacity (L) FVC 2.60 (0.96) 2.52 (0.97) NS








Residual volume (L) RV 3.79 (1.38) 3.72(1.21) NS





Minute ventilation (L/min) VE 10.1 (2.30) 9.5 (2.13) NS










Mean inspiratory flow rate Vt/TJ 0.47 (0.13) 0.46 (0.11) NS





Ratio ofTptef to exp. Time Tptef/TE 0.13 (0.07) 0.14(0.07) NS
Flow at 75% of tidal volume (L/s) ef25 0.24 (0.06) 0.22 (0.05) NS







Volume expired in first sec. of tidal
breath (L)
TBEV, 0.34 (0.09) 0.34 (0.11) NS
Tidal peak expiratory flow rate (L/s) TPEF 0.49 (0.13) 0.30(0.15) NS
Inspiratory capacity (L) IC 2.22(1.02) 2.36 (0.96) NS
Table 5.10: Conventional and tidal breathing variables. Mean (SD) (or
Median (interquartile range) for data not normally distributed) values for
spirometry, whole body plethysmography and tidal breathing variables pre and
post placebo treatment.
Pre treatment values compared with post treatment values by 2 way RM
ANOVA with pairwise comparisons using Student-Newman-Kuels test.
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Figure 5.21: Changes with treatment. Data for conventional and tidal
breathing variables pre and post bronchodilation (open) or placebo treatment
(hatched).
Columns represent the mean group measurement with standard deviation bar.
n = 28 (sGaw n= 18 ). t = P < 0.05 for 2 way RM ANOVA.
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non significant rises in Vx and frequency. The increase in Vx (mean VT 0.67 L pre and
0.73 L post bronchodilation), along with the decrease in Ti (mean T] 1.55 s pre and
1.45 s post bronchodilation), resulted in Vt/T] (a measure of respiratory drive)
increasing significantly after bronchodilator treatment (median value 0.41 L/s pre
and0.52 L/s post bronchodilation). Three of the novel tidal breathing variables (EF25,
TBEVj and TPEF) showed statistically significant increases post active treatment but
not post placebo.
5.4: Discussion.
These data show that tidal breathing recordings can be used to detect changes
in expiratory airflow following bronchodilators and that these changes correlate with
bronchodilation as judged by conventional plethysmographic techniques.
Our results show that although TPTef/Te in our group of patients is similar to
that in the group studied by Morris [59] it does not correlate with baseline FEVi or
sGaw nor is the change post bronchodilation statistically significant. It was therefore
concluded that TPTef/Te is not a sensitive indicator of changes in airflow obstruction.
The variables TPTef and TEEV), did not show significant increases after
bronchodilation nor did they correlate to our gold standard of airflow obstruction,
airways resistance (r = 0.19, p = 0.18 and r =0.06, p = 0.68 respectively), and so again
it was concluded that these were not sensitive indicators of airflow obstruction. This
left three novel tidal breathing variables that correlated to conventional measures of
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airflow obstruction and increased significantly after bronchodilation but not after
placebo treatment. It is these three variables (TBEVi, TPEF and EF25) that are further
studied in the following chapters.
One method for comparing the sensitivity and specificity of the new variables
for assessing airflow obstruction would be to construct receiver-operator curves [95],
however sensitivity and specificity can only be calculated if there is an agreed gold
standard for the novel variables to be measured against (i.e. something which tells you
the "true positive" rate of bronchodilator response). As there is no agreed gold
standard for measuring airflow obstruction this approach is difficult to apply here.
Due to the methodology chosen for breath averaging it was not possible to
produce a complete averaged breath from which to measure the tidal breathing
variables. Instead separate portions of each recorded breath are averaged in discrete
"time bins" then the variables are measured from the bin-averaged breath. Alternative
methods of analysis include the production of an averaged breath by normalising
disparate breath lengths (method of Benchetrit and Shea [21, 22]) or calculating each
variable for each breath and averaging the results (method ofMorris and Williams [61,
62]). Each approach has advantages and disadvantages, as stated elsewhere in this
thesis. Primarily the production of a whole averaged breath by normalisation of the
breath length would lead to distortion of time-dependent changes, and the analysis of
single breaths would be particularly sensitive to random noise and cardiac artefact.
The bin-averaging method employed in this thesis has none of these disadvantages but
does not yield a complete averaged breath. At present there is no one perfect method
of averaging a time-varying signal and so the method chosen was the one that was felt
to be least likely to distort the variables to be measured (i.e. none of the chosen
variables required the complete expiratory profile for its measurement).
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In the present study bronchodilators had a number of different effects on
resting breathing. Minute ventilation increased significantly; this could be due to
either an increase in respiratory drive or increased airway calibre or both. The results
show that after bronchodilation mean inspiratory flow rate (an indirect measure of
respiratory drive) was significantly increased, and airways resistance significantly
decreased. This suggests that it may be a combination of both mechanisms that leads
to the increase in tidal expiratory flow as reflected in the increase in the novel tidal
breathing variables, TBEVi, TPEF, and EF25. However to distinguish fully between
these two mechanisms requires reliable measures of intrabreath resistance and
respiratory drive and is beyond the scope of this thesis.
In this group of patients inspiratory capacity did not change significantly after
bronchodilation thereby indicating that FRC was unchanged. However there was a
significant reduction in RV after bronchodilation in the subgroup of patients that had
RV measurements. This was also found in a study by O'Donnell et al [96] who found
that small but consistent changes in TLC led to IC and VC underestimating changes in
FRC in 43% of their patient group. In their study, RV changed more than other
volume measurements and was therefore better at detecting a reduction in air trapping
after bronchodilation. It was not however practical using the open circuit required for
the present studies to measure RV directly, so the compromise of deducing changes in
FRC from IC was used.
The degree of correlation between the tidal breathing variables and FEV] was
different than that between the tidal breathing variables and sGaw. This raises the
question of what is the gold standard for measuring airway obstruction with which to
compare these novel tidal breathing variables. Various groups [97-100] have studied
the response to bronchodilators as measured by spirometry (FEVi) and
plethysmography (sGaw) and found that sGaw correlates better than FEV, with
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subjective benefit [97, 98] and that increases post bronchodilator were larger for sGaw
than for FEVj [99, 100], This may be important when using FEV] to determine the
reversibility of airflow obstruction to bronchodilation or steroid response as patients
could be incorrectly categorised as non-responsive to treatment.
In conclusion, three novel tidal breathing variables have been identified which
change in an expected and reproducible way following bronchodilation, and which
correlate well with conventional variables of airflow resistance. These variables can
be measured without the need for special breathing manoeuvres and with relatively
inexpensive equipment.
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All physiological measures have some degree of natural variability measure to
measure. This variability is a result of changes in patient performance and equipment
accuracy. In order for any change in variable to be attributed to an intervention of any
kind the magnitude of change must exceed the natural variability associated with that
variable. It is therefore important when defining and validating any new variable that
the natural variability inherent in it is determined.
The standard index for describing the natural variability is the coefficient of
repeatability determined from consecutive measurements made within a short time
period with no intervention between them.
6.2: Method.
Data collected from the pilot studies described in chapter 5 were analysed to
determine the natural variability in the novel tidal breathing variables.
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The 15 minutes of data collected were divided into 3 sets of 5 minutes and the
novel tidal breathing variables described in chapter 5.1 calculated for the second and
third data sets, the first 5 minutes of data were not used as in these first studies there
was no set acclimatisation time and so the first 5 minutes was used as the
acclimatisation time (all subsequent studies had an acclimatisation time of 2 minutes as
part of the protocol). These two sets of data were then used to calculate the coefficient
of repeatability for each variable.
For the conventional variables of spirometry and airways resistance, the three
technically satisfactory measurements obtained for the study described in chapter 5
were used. Again, for the reason stated above, the second and third measurements were
used to calculate the coefficient of repeatability.
Once these coefficients were calculated for each variable, the data collected pre
and post bronchodilation were reanalysed to determine if the magnitude of change was
greater than the natural variability.
6.3: Results.
6.3.1: Calculation of 95% Confidence Intervals.
Data were collected in 25 patients for the novel tidal breathing variables, 17
subjects for airways resistance and 27 patients for FEVi.
The paired data for the second and third periods is shown in table 6.11. The












Period 2 3 2 3 2 3 2 3 2 3
Patients 1 0.63 0.62 0.56 0.55 130 141 211 204 245 235
2 2.32 2.32 1.23 0.28 187 182 377 357 557 505
3 0.8 0.83 0.61 0.70 249 264 390 422 489 551
4 0.49 0.56 0.45 0.45 203 202 253 243 298 283
5 0.94 1.03 0.54 0.54 233 209 314 299 392 375
6 0.76 0.76 0.56 0.50 357 380 600 610 809 803
7 1.45 1.4 0.24 0.21 206 215 487 483 668 674
8 1.84 2 1.07 1.12 265 283 351 363 445 470
9 1.76 1.64 0.56 0.56 239 207 278 253 320 294
10 2.68 2.84 0.26 0.28 264 223 396 397 527 506
11 0.29 0.33 0.89 0.96 233 241 365 390 416 456
12 1.16 1.09 0.44 0.46 209 234 368 410 588 670
13 0.67 0.66 0.80 0.62 258 242 300 289 501 460
14 1.28 1.28 0.30 0.34 167 199 393 437 483 509
15 0.64 0.6 0.99 0.92 166 185 231 248 343 368
16 0.65 0.56 0.40 0.37 271 275 345 361 549 585
17 0.44 0.46 0.57 0.55 259 281 433 445 794 752
18 1.28 1.2 189 198 262 247 310 295
19 1.48 1.4 272 274 369 362 473 450
20 0.84 0.92 226 220 278 247 344 325
21 1.28 1.32 182 194 357 363 566 584
22 1.48 1.44 294 307 383 380 507 494
23 1.32 1.28 305 290 401 410 469 460
24 1.28 1.32 266 280 355 363 542 529
25 3.16 3.2 221 200 346 319 433 433
26 0.77 0.76
27 1.6 1.84
Table 6.11: Paired data for periods 2 and 3 used to calculate 95% confidence
intervals for FE\A,, sGaw, EF25, TBENA, and TPEF.
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repeated measures) for FEV) was 170 ml, sGaw 0.13 /kPa/sec, TBEVi 42 ml, EF25 39
ml/sec and for TPEF was 67 ml/sec.
6.3.2: Analysis of Effect of Bronchodilation.
Figure 6.22 shows the graphical representation of absolute change in novel tidal
breathing variables (TBEV], TPEF and EF25) post active treatment compared to
absolute change in A) FEV) (n=49) and B) sGaw (n=39) post active treatment; along
with the 95% confidence intervals for repeated measurement of each variable without
intervention (dotted lines).
These graphs show that for each of the variables some of the patients have an
increase in both the conventional variable and in the tidal breathing variable, the
numbers of patients is shown in table 6.12a. There are however subsets of patients who
show either an increase in the conventional measure but a decrease in the tidal breathing
variable and vice versa. The graph also shows that there are a proportion of patients
who do not demonstrate increases greater than natural measure to measure variability
and that this proportion of patients is greater for the tidal breathing variables than for
FEV) or sGaw.
A number of patients did not show changes in FEV1 greater than the natural
variability (16/49 33%) and of these a small proportion showed changes in the novel
variables greater than the natural variability (table 6.12b). A number also did not show
changes in sGaw greater than the natural variability (9/39 23%) and of these a
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Figure 6.22: Changes in novel tidal breathing variables compared to
conventional variables following bronchodilation.
The dotted lines represent the 95% confidence limits for repeated measurement
of each variable without intervention.
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(a)
Novel variable (1) fe\a| (n=33) (ii) sGaw (n=30)
tbenai 16 (48%) 12 (40%)
tpef 14 (42%) 10 (33%)
ef25 12 (36%) 10 (33%)
(b)
Novel variable (i) fevi (n=16) (ii) sGaw (N=9)
tbe\a| 2 (12%) 2 (22%)
tpef 1 (6%) 1 (11%)
ef25 1 (6%) 0 (0%)
Table 6.12: (a) The number (percentage) of patients who had a significant
change in (i) FEVt or (ii) sGaw and in the novel tidal breathing variable, (b) The
number (percentage) of patients who did not have a significant change in (i)




In order to be able to interpret any change in respiratory variable after
intervention the natural variability of the measure must be taken into account.
Tweeddale et al [69] examined the short-term variability of FEV, in patients with
obstructive ventilatory defects. They found that in order to exclude natural variability
with 95% confidence FEV] had to increase by more than 160 ml. In the present study
this value was calculated to be 170 ml. No study has been reported examining this
value for sGaw but this study concludes that an increase of more than 0.13 /kPa/sec is
needed to exclude natural variability.
The values for TBEVh EF2s and TPEF were calculated to be 42mls, 39ml/sec
and 67 ml/sec respectively. Flowever this does not allow any determination of what
change is required for a clinically significant change in symptoms.
To examine the change in variables following bronchodilation in light of the
natural variability the data collected in the study described in chapter 5 were plotted
along with the 95% confidence interval calculated here (figure 6.22).
Although patients were recruited for the study had to have had previously
demonstrated reversibility to bronchodilators by spirometry a proportion did not show
changes greater than the natural variability in FEV) or in sGaw. However of these there
was a proportion of patients who showed increases greater than variability in the novel
tidal breathing variables (table 6.12b). This raises again the question ofwhat is the gold
standard measure of airflow obstruction.
Van Noord et al [101] looked at this when comparing the application of forced
oscillation technique to variables of forced expiration and plethysmography airways
119
resistance in assessing airflow obstruction. They performed multivariate analysis of
differences between pre and post bronchodilator values and found that the effect of
salbutamol was best described by a combination of Raw and FVC when looking at
percentage change and by a combination of sGaw and FVC when looking at absolute
change.
Specific conductance (sGaw) may be the better gold standard when looking at
airflow obstruction because it measures only the conductance of the airways whereas
FEVj and FEVj/FVC integrate changes of dynamic airways function, lung recoil and
the forces applied by the respiratory muscles into the one measure and do not allow for
individual parts to be studied.
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Chapter 7: Reproducibility of tidal breathing variables.
7.1: Introduction.
Chapter 6 examined the measure-to-measure (within day) variability of the
novel tidal breathing variables. However before any new variable can be used routinely
the reproducibility of the measure against time must be determined. The following
study examined both short-term (within 2 weeks) and long-term (over 6 months)
reproducibility.
7.2: Method.
To answer the question of the short-term reproducibility of the variables data
from the group of patients who had attended for testing within two weeks were
analysed.
For the long-term reproducibility patients, who had attended for the previous
studies, were asked to repeat the study after 6 months.





45 patients attended the laboratory on two separate occasions a mean (SD) 10
(10) days apart. Their mean (SD) age was 66 (10) years and they had a baseline %pred
FEVi of 44% (19)%. Spirometric (FEV,, FVC and RVC), airways resistance (Raw and
sGaw), breathing pattern (VT and VE) and novel tidal breathing (TBEV), TPEF and
EF25) variables were looked at on both occasions. None of these variables showed any
statistically significant difference between the two study days at baseline (table 7.13)
and the 95% confidence limits of the difference between visits are of a similar
magnitude for all variables when corrected for the different sizes of the actual variable
value. Figure 7.23 shows the individual patient differences as Bland and Altman plots.
7.3.1.2: Percentage change after bronchodilation.
44% of the group of patients described above (20 patients) also had
measurements made after nebulisation of ipratropium bromide and salbutamol on two
occasions. The two study days were a mean (SD) 6(3) days apart and the patients'
mean (SD) age was 70 (7) years and they had a baseline %pred FEVi of 44% (16)%.
There was no significant difference in any of the variables studied between the two
study days (Table 7.14). The 95% confidence limits of the difference between visits are
of a similar value for all variables (table 7.14) although RVC and Raw show the
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FE\A| (L) 1.31 1.31 1.31 NS 0.37 28.2
FVC (L) 2.63 2.70 2.67 NS 0.75 28.1
RVC (L) 3.01 3.03 3.02 NS 0.96 31.8
Raw (kPa.sec/L) 0.42 0.42 0.42 NS 0.19 45.2
sGaw (/kPa/sec) 0.59 0.60 0.60 NS 0.20 33.3
VT(L) 0.63 0.61 0.62 NS 0.45 24.2
Ve (L) 9.7 10.2 10.0 NS 4.06 40.6
EF25 (ml/sec) 236 249 242 NS 99.25 41.0
TBEV-( (ml) 349 363 356 NS 149.63 41.2
TPEF (ml/sec) 467 494 480 NS 185.64 38.7
Table 7.13: Group mean values for baseline values for the two study days
less than 2 weeks apart.
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Figure 7.23: Bland and Altman plots showing comparison of visit 1 and visit 2
baseline data.
Solid line is the mean difference and dashed lines are the 95% confidence limits
of the difference between visit 1 and visit 2 for short-term reproducibility.
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95% CL of between
visit difference
FEVT (L) 21.37 19.79 20.58 NS 42.60
FVC (L) 21.10 20.66 20.88 NS 35.60
RVC (L) 12.41 11.37 11.89 NS 18.78
Raw (kPa.sec/L) -25.68 -25.67 -25.68 NS 25.60
sGaw (/kPa/sec) 47.48 52.64 50.06 NS 62.18
Vt(L) 12.55 9.99 11.27 NS 46.98
Ve (L) 13.82 11.40 12.61 NS 56.20
EF25 (ml/sec) 10.78 3.96 7.37 NS 49.93
TBEXAi (ml) 12.86 5.23 9.05 NS 41.63
TPEF (ml/sec) 10.66 4.77 7.72 NS 38.66
Table 7.14: Group mean values for percentage change after bronchodilation
values for the two study days less than 2 weeks apart.
NS = not significant.
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smallest dispersion around the mean (95% CL of 18.78 and 25.60 respectively).
7.3.2: Long-term reproducibility.
7.3.2.1: Baseline.
14 patients attended the laboratory on two separate occasions a mean (SD) 364
(176) days apart. Their mean (SD) age was 63 (11) years and they had a baseline %pred
FEVi of 50% (17%). The same variables were looked at as for short-term
reproducibility and none of these showed statistically significant difference at baseline
(table 7.15). The 95% confidence limits of the difference between visits were of a
similar magnitude for all variables when corrected for the different sizes of the actual
variable value (table 7.15) although all values were larger than for the short-term
reproducibility. Figure 7.24 shows the individual patient differences as Bland and
Altman plots.
7.3.2.2: Percentage change after bronchodilation.
13 patients attended the laboratory on two separate occasions a mean (SD) 338
(151) days apart. Their mean (SD) age was 63 (11) years and they had a baseline %pred
FEV) of 50 (18)%. There was no statistically significant change of any of the variables
between the two study days (table 7.16). The 95% confidence limits of the difference
between visits were of a similar value for all variables (table 7.16) and like the baseline
results were greater than for short-term reproducibility.
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FEV-i (L) 1.49 1.67 1.58 NS 0.98 63.3%
FVC (L) 2.72 3.04 2.88 NS 1.65 57.3%
RVC (L) 2.90 3.09 5.99 NS 1.71 28.5%
Raw (kPa.sec/L) 0.32 0.35 0.34 NS 0.22 64.7%
sGaw (/kPa/sec) 0.87 0.82 0.85 NS 0.23 27.1%
Vt(L) 0.73 0.68 0.71 NS 0.33 46.5%
Ve(L) 11.32 10.39 10.86 NS 6.10 56.1%
EF25 (ml/sec) 269 246 258 NS 157.03 60.9%
TBEV1 (ml) 404 389 397 NS 193.30 48.7%
TPEF (ml/sec) 534 549 542 NS 277.07 51.1%
Table 7.15: Group mean values for baseline values for the two study days
more than 6 months apart.
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Figure 7.24: Bland and Altman plots showing comparison of visit 1 and visit 2
baseline data for visits more than 6 months apart.
Solid line is the mean difference and dashed lines are the 95% confidence limits
of the difference between visit 1 and visit 2.
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95% CL of between
visit difference
FEV1 (L) 17.78 22.73 20.26 NS 44.13
FVC (L) 16.60 16.49 16.55 NS 61.78
RVC (L) 25.89 13.82 19.86 NS 59.35
Raw (kPa.sec/L) -31.86 -33.00 -32.43 NS 27.38
sGaw (/kPa/sec) 60.60 72.37 66.49 NS 54.55
Vt(L) -0.96 9.74 4.39 NS 42.46
VE (L) 3.44 10.67 7.06 NS 51.36
EF25 (ml/sec) 6.87 18.25 12.56 NS 61.34
TBEV-i (ml) 7.31 13.62 10.47 NS 42.62
TPEF (ml/sec) 9.74 13.70 11.72 NS 41.25
Table 7.16: Group mean values for percentage change after bronchodilation
values for the two study days more than 6 months apart.
NS = not significant.
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7.4: DISCUSSION.
The reproducibility of any new physiological variable is important for its
acceptability for routine use.
In a study by Noseda et al [102] a number of different variables of lung function
and exercise capacity were investigated for reproducibility and clinical relevance in
patients with COPD. They found that FEV| was among four variables that showed the
greatest clinical potential for functional assessment.
A year later Vollmer [103] reported that FEVi was more reproducible than
single breathing nitrogen test variables and FEVi/FVC when measured over a 9 to 11
year period. This would imply that FEVi was the most stable measure and so the best
indicator of lung function, however it may also reflect that FEVi was not as sensitive to
small changes in lung function as the other variables and failed to pick up slow declines
or in lung function.
Enright et al [104] investigated the short-term variability of FEV! (mean 25
days apart). The mean difference between FEVi values was 10.2 ml with a mean
intraindividual variability of 141 ml and a coefficient of variability (CV) of 5.8%.
In this study for FEVi the mean difference between values for short-term
variability (mean of 10 days) was 2.8 ml. For long-term variability (mean of 364 days)
the mean difference in FEVi values was 175 ml.
One difficulty in comparing the reproducibility of the novel variables to the
conventional variables was that, for baseline values, the magnitudes of the values were
different. An average FEVi was for this patient group was 1.4 L whilst the average
TBEVi was 350 ml therefore absolute differences and 95% confidences limits (95%
CL) of the data between two study days are of little value. To try to overcome this the
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95% CL were corrected for the mean value size for the variable by reporting it as a
percentage of the mean value. This showed that the reproducibility for novel tidal
breathing variables and conventional variables were similar and that for all variables
reproducibility was better for the short-term than the long-term time periods.
When looking at the percentage change after bronchodilation on different study
days the magnitude of the response was similar for all variables and so the 95% CL
could be compared directly. Again the values were similar for all variables and better
for short-term reproducibility than long-term.
In summary this study has shown that the reproducibility of the novel tidal
breathing variables (EF25, TBEVi and TPEF) is similar to that for the conventional
routinely used variables ofFEVj, FVC, RVC and sGaw.
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Chapter 8: Correlation with Subjective Benefit.
8.1: Introduction.
The previous study has defined the minimum change that exceeds natural
variability for each variable. However as Tweeddale et al [86] stated, in patients with
severe obstruction smaller increases may be clinically relevant, whereas in patients
with mild disease this minimum increase may not be noticeable. So not only must the
natural variability be calculated for any new variables but also the increase necessary
for clinical benefit to be felt.
For patients with chronic obstructive pulmonary disease the predominant
complaint and one of the main reasons for seeking medical advice is dyspnoea [64], In
the early stages of the disease this is seen on exertion only, but in latter stages of
COPD dyspnoea is also experienced at rest. Dyspnoea has been quoted [105] as being
the main incapacitating symptom and the most common reason that exercise is
curtailed.
Clinically the evaluation of the level of dyspnoea experienced by patients with
COPD is important. Ramirez-Venegas [92] stated that the major reason for the
prescription of bronchodilator medication in COPD was to improve symptoms,
including dyspnoea. Therefore much work has been carried out to determine the best
test of dyspnoea in patients with COPD [5, 106, 107],
One of the main criticisms of FEV, was that it correlates weakly [4,5] or not at
all [6] with the degree of dyspnoea. It has also been reported [7] that patients tested
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for reversibility to bronchodilators sometimes report symptomatic benefit but show no
improvement in FEVi.
It is therefore preferable that any new measure of airflow obstruction should
correlate to the level of dyspnoea and to subjective benefit following treatment.
The aim of this part of the programme of studies was to determine if the novel
tidal breathing variables of airflow obstruction described in chapter 5.1 correlated to
dyspnoea; in both the baseline level and the improvement after nebulised
bronchodilator.
The hypothesis was that patient's perception of changes in dyspnoea after
nebulisation would correlate to the changes in physiological measures of airflow
obstruction.
8.2: Method.
Dyspnoea scores were included prospectively in 35 of the tidal breathing
recordings reported in chapter 5 for pre and post bronchodilation and in 11 patients pre
and post placebo treatment.
The protocol for each study day was the same as described in chapter 5 section
2.2. In addition patients were asked to score their breathlessness on a 20 cm visual
analogue scale (VAS) [108] (figure 8.25) at the start of testing, and after nebulisation
(figure 8.26).
For baseline dyspnoea scores the subjects were asked to "Mark on the line
how breathless you feel at the moment. The line goes from not at all breathless at one
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were asked to "Mark on the line how much your breathlessness has changed from the
start of the study to now, if at all. The line goes from very much worse to very much
better with no change in the middle".
In a subgroup of patients dyspnoea scores were also measured after the first set
of spirometry was performed to assess if performing spirometry itself caused a change
in patient perceived dyspnoea.
Twenty subjects performed the bronchodilator arm of the above protocol on two
different occasions either within two weeks of each other, so that the reproducibility of
the correlation of tidal breathing variables with dyspnoea could be examined.
8.3: Results.
8.3.1: Baseline.
Table 8.17 shows the Spearman's coefficient of correlation (r) and p values for
spirometric, plethysmographic and tidal breathing variables with VAS score of
breathlessness. No variable correlated with baseline breathlessness.
The range of scores was 1.8 to 19.1 with no patient scoring not breathless.
There was no significant difference between patients who subsequently showed no
FEV, response (less than 160 mis) to bronchodilators (VAS mean 10.1 range 1.8 to
15.9, N=9) and those who did show response in FEVi (160 ml or greater) (VAS mean
10.3 range 2.1 to 19.1, N=26).
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Variable Baseline Change post
Placebo Treatment Placebo &
treatment
FEV, NS NS NS NS
FVC NS NS NS NS
RVC NS NS NS NS
Raw NS NS NS -0.45 /0.002
SGaw NS NS NS 0.46/0.001
VT NS NS 0.33 /0.049 NS
Ve NS NS NS 0.46/0.001
ef25 NS NS NS NS
TBEV, NS NS 0.40 / 0.02 0.37/0.010
TPEF NS NS NS 0.29/0.049
Table 8.17: Correlation of baseline VAS dyspnoea score with respiratory
variables and change in VAS score of dyspnoea with absolute change in
respiratory variables post nebulisation.
Values represent Spearman's coefficient (Rs) / p value. NS = not significant.
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8.3.2: Change after bronchodilation and placebo.
The mean change in the dyspnoea score after spirometry but before
bronchodilation was -0.5cm. A Mann-Whitney rank sum test showed that this small
decrease was not statistically significant (p=0.76) and so all values quoted below are for
the change in VAS score from baseline to after nebulisation.
The mean (SD) change in dyspnoea post nebulised bronchodilator was 4.9 (1.9)
with a range of 0.8 to 8.1.
Table 8.17 shows the Spearman's coefficient of correlation (r) and p values for
the absolute change of spirometric, plethysmographic and tidal breathing variables after
bronchodilator and placebo nebulisation with subjective benefit as measured by change
in VAS score. For all nebulised interventions (placebo and active) the change in
physiological variables was plotted against change in dyspnoea in Figure 8.27.
Improvements in FEVi, FVC and RVC were not correlated with improvements
in dyspnoea whereas Raw, sGaw, and VE were, along with the novel tidal breathing
variables TBEV| and TPEF. The correlation between these variables and change in
dyspnoea is shown (figure 8.27) along with the change in dyspnoea after either
bronchodilator or placebo treatment for individual values and mean value (figure 8.28).
8.3.3: Effect of saline.
The mean (SD) change in dyspnoea post nebulised saline was 1.08 (2.40) with a
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Figure 8.27: Correlation of change in dyspnoea with absolute change post
active (O) and placebo (•) treatment for spirometric, plethysmographic and tidal
breathing variables.
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Figure 8.28: Change in VAS score dyspnoea after active treatment
(salbutamol and ipratropium bromide) and placebo. Open circles represent
individual data and closed circles represent mean value with standard deviation.
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There was no correlation between change in breathlessness and absolute change after
saline treatment for any variable (table 8.17).
8.3.4: Reproducibility of Dyspnoea Change.
20 patients performed the bronchodilator arm of the above protocol on two
separate occasions. The mean (SD) number of days between the two visits was 6 (3)
with a range of 2 to 15 days. Paired T-tests showed there was no significant difference
between the change in dyspnoea score on the two visits. Figure 8.29 shows individual
patient data for each visit along with the group mean (SD) for each visit.
8.4: Discussion.
Symptomatic benefit of treatment in COPD is recognised as an important
outcome measure in both disease management [105, 107, 109, 110] and in trials of new
treatment [ 106, 109],
The 1994 BTS guidelines for nebuliser use in COPD [66] states "After an
assessment process the clinician must decide with the patient if the nebuliser treatment
has produced subjective and objective benefit". The guidelines also state that if patients
experience a subjective benefit from nebuliser treatment, even if no clear improvement





Figure 8.29: Change in dyspnoea score after bronchodilation on 2 separate
occasions.
For individual patient data (•) and group mean and SD (o).
NS = no significant difference (t-test).
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Subjective benefit in the absence of a change in conventional physiological
variables may occur due to placebo effect or because physiological changes are
occurring which are not detected by the conventional variables. In a study by Khan and
O'Driscoll [111] it was found that nebulised isotonic saline caused a reduction in
breathlessness at rest which was not present when an inactive nebuliser system was
used, this was termed a placebo response. In this study they was no significant change
in dyspnoea scores after placebo treatment. The possibility that undetectable (by
conventional variables) physiological changes were occurring would be supported if
new measures of airway obstruction, which are to be used to assess the efficacy of
treatment, were correlated with subjective benefit.
The present study confirms the results of a previous study by Smith [7] that
FEVi, FVC and RVC do not correlate to change in dyspnoea. Further this study shows
that the present gold standard of airway obstruction, sGaw does correlate to change in
dyspnoea as reported previously [97, 98]. It has also shown that two of the novel tidal
breathing variables described in chapter 5.1, TBEV) and TPEF, were correlated with
changes in dyspnoea.
No variable showed any correlation with baseline dyspnoea. This may be
because the patient perceived level of breathlessness is a very individual measure.
Some patients with severe airflow obstruction score themselves as not breathless,
whereas other patients with more mild disease score themselves as very breathless.
This is likely to be because patients shift their scale of breathlessness depending on
individual experience. This large intersubject variability in dyspnoea scoring will
obscure the effects of airflow obstruction on dyspnoea scores in a population.
A limitation of the present study is that the measurement of breathlessness was
made at rest and not all patients with COPD experience this. Therefore they may not
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feel any benefit of bronchodilators at rest but only on exertion. However in the
population study no patient scored 0 (not breathless) on the VAS, the lowest score being
1.8 (of a maximum score of 20) and only 5/35 (14%) had a score of less than 3. There
was also no significant difference in resting breathlessness between those patients
deemed responsive on FEV, criteria and those unresponsive.
A number of variables correlated with change in dyspnoea when looking at the
response to treatment. This may be because although the actual level of dyspnoea is
variable between patients the change after treatment is more consistently scored within
patients.
As these measures are subjective patients were asked at the end of the final visit
if they realised that they had been given different treatments on the different visits in
order to determine if the blinding had been adequate. No patient said that at the time
they thought they had been given different treatments but approximately 25% said that
looking back it would explain why they had felt better after some study days than
others.
In summary, in contrast to FEVi, the absolute change in airways resistance,
specific conductance, minute ventilation and the tidal breathing variables, TBEV) and
TPEF correlate with subjective benefit after nebulised treatment.
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Chapter 9: Discussion
The hypothesis addressed in this thesis is that novel variables measured from
tidal breathing expiratory flow patterns can be used to assess airflow obstruction.
The studies reported in this thesis have shown that it has been possible to
identify aspects of the tidal breathing expiratory profile which correlate with the degree
of airflow obstruction present and which change in a physiologically plausible way in
response to bronchodilator therapy.
This concluding chapter considers the success of developing the measurement
and analysis protocols and the usefulness of the novel variables in a clinical setting.
The need for an alternative measurement of airflow obstruction to FEVt is
becoming more accepted with groups looking at the use of other measures from
spirometric manoeuvres to determine patients' response to inhaled treatment. This is
confirmed in Chapter 2, which showed that if only FEV, was used to assess the
response to bronchodilator therapy in patients with diseases involving airflow
obstruction then potentially 21% of these patients would be denied treatment that may
be beneficial for them.
The use of tidal breathing to assess changes in breathing due to disease has been
explored for many years in animals and infants because of the inability of these groups
to perform conscious breathing techniques such as the forced expiratory manoeuvre.
Tidal breathing variables have been described that correlate with the presence and
severity of obstructive lung disease in these groups.
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9.1: Identification of novel variables and protocol development.
The study described in chapter 5 showed that there are three novel tidal
breathing variables which increased significantly after bronchodilation. These were
TBEV,, TPEF and EF25.
Two of these variables are measured from the early portion of the expiratory
flow profile and one from near the end of the expiration. The reason that the majority
of the variables were from the start of expiration may be explained from observation of
the individual breaths. It was noted that the beginning of expiration was less variable
than the end of expiration. Some patients started inspiration before they had reached
FRC (no expiratory pause) whereas others showed expiratory pauses of up to 20
seconds in length.
This variability in the end of expiration makes the production of an averaged
breath difficult. To try to overcome this, the computer algorithm used for breath
analysis excluded expiratory pauses. This was achieved by defining a threshold level of
flow rate at which the expiration was considered finished. It is unknown if small
changes in this threshold would make a difference to the value of variables measured
near the end of the breath or if small changes in the flow profile had been lost.
Another consideration in determining the best protocol for the collection of the
data was the duration of the collection period and of any pre-collection acclimatisation
period.
Early pilot studies showed that it was important to allow the patients time to
acclimatise to the breathing equipment but this leads to the possibility that during this
time the patients may have been altering their breathing pattern to suit breathing on the
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equipment, or that the breathing may have changed whilst the equipment was being
fitted and that during the acclimatisation period it was returning to normal.
As there is no way to test this, the equipment which was used in the studies was
that which was thought likely to have the least effect on the breathing pattern, kept
equipment dead space to a minimum, had minimum resistance to airflow and allowed
the subjects the choice to mouth or nose breathe.
The collection time was initially chosen as 15 minutes, however some patients
found themselves getting drowsy near the end of the collection period despite having a
taped story to listen to.
To minimise the time taken for measurements, results taken from a shorter
collection time were compared with those from a longer collection time. The study
described in chapter 3.3.1 showed that data collected in 5 minutes did not differ
significantly from data collected over 15 minutes. It was decided to still use the taped
story even for this shorter collection time but this may not have been necessary and
should be further studied. The reduced measurement period also meant that the total
time for the data to be collected, including time to explain the procedure and to attach
the equipment, was reduced to approximately 10 minutes. This is the same if not
shorter than the time it takes to perform three forced expirations to BTS standards and
makes the protocol more acceptable for everyday use.
All the analysis was performed by one investigator JMM, therefore it would be
necessary for another investigator to analyse the data as well to determine how
investigator specific the results are, e.g. do different investigators identify the same
aberrant breaths for exclusion from analysis.
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9.2: correlation with conventional variables.
The three variables (TBEVi, TPEF and EF25) identified in chapter 5 to change
post bronchodilation were also examined to determine if they correlated to the
conventional variables of airflow obstruction. As there is 110 accepted gold standard for
measuring airflow obstruction both FEVi and sGaw were studied.
TBEVi and EF25 correlated better with sGaw and FEVi than TPEF (figure 5.20)
and the correlations of TBEVi and TPEF with sGaw were stronger than with FEVi.
9.3: Variability.
The measure to measure variability was examined and reported in chapter 6.
The 95% confidence interval for each variable was calculated but in order to compare
these confidence interval between variables of different magnitudes the ratio of the
confidence interval to the average value was calculated (table 9.18). This shows that the
variability of the novel variables is comparable to that of FEV1 and less than that for
sGaw.
9.4: Reproducibility.
The short and long term reproducibility of the variables were examined and reported in




Average value (X) CI:X
fev, 170 ml 1233 ml 0.14
sGaw 0.13 /kPa/sec 0.56 /kPa/sec 0.23
tbevi 42 ml 354 ml 0.12
tpef 67 ml 483 ml 0.14
ef25 39 ml 234 ml 0.17
Table 9.18: Comparison of the measure-to-measure variability for
conventional and novel tidal breathing variables.
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for either baseline or percentage change post bronchodilator values measured over
short-time period (< 2 weeks) or a longer time period (> 6 months).
As with variability the 95% confidence interval of the between visit difference
as a percentage of the mean value of the variable was calculated to allow comparison of
the different variables.
For both short and long term reproducibility the values for the novel variables
are similar to those for the conventional variables. For all values the longer term
reproducibility was worse than for short term. This greater variability over long periods
is a common feature of biological measurements.
9.5: Patients with no response to bronchodilators.
In all the studies described in this thesis one of the inclusion criteria for patient
recruitment was that they had previously shown significant reversibility to
bronchodilators on spirometry.
However, on the actual study day some patients did not show reversibility in the
conventional variables. In order to determine if these patients who would have been
described as unresponsive to bronchodilators on conventional testing showed increases
in the novel variables this sub-group of patients was tested. The data in chapter 6 shows
that of the 33% of patients who showed no significant change post bronchodilation by
FEVi criteria 12% showed increases in TBEV,, and 6% for TPEF and EF25. For sGaw
23% did not show response to bronchodilators and of these for the novel variables
TBEV], TPEF and EF25 the percentage who did show increase were 22%, 11% and 0%
respectively.
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Because the number of patients in this sub-group was small (N=16 for FEV|
and N=15 for sGaw) it would have been better to include a group of patients who had
not previously shown response to bronchodilation to study this in more detail.
9.6: Comparison of present studywith previous work.
The majority of previous studies investigating the possibility of using tidal
breathing to assess airflow obstruction have been carried out in children. They have
involved a variety of different protocols as outlined in chapter 1.9.2.
In the studies with younger children the data collection was performed with the
subjects sedated, this is neither practical nor desirable when working with adults as it is
not known what effect sedation would have on the breathing pattern.
In the study on adults by Morris and Lane [59] TPtef/Th was examined in
patients with airflow obstruction and normal subjects to see if this variable could
distinguish between the two groups, which it did although on an individual basis there
was overlap between the groups.
Morris and Lane [59] overcame the problem of breath variability by recording
10 consecutive breaths, measuring the value of the new variables for each breath and
then averaging the results. This has the advantage of being able to use all of the breath.
However it was not stated if any breaths were excluded due to swallowing, coughing,
sighing etc. or if an acclimatisation period was allowed. They did however state that the
variability of the breathing pattern was less for the obstructed group than for the normal
subjects. The flow data were collected using a heated pneumotach and a mouthpiece,
which in a later study they reported had a dead space of 120 ml. Therefore although
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they imposed mouth breathing on the patients, with all the changes that this is reported
to have on the breathing pattern [78-84] they have kept the dead space to a minimum.
In the present study all flow data were collected using a facemask and ultrasonic
flowmeter, thereby allowing the patients to breath either orally or nasally and hopefully
decreasing the changes in breathing pattern due to the equipment, this meant an increase
in the dead space to 175 ml but this was felt to be an acceptable compromise.
The study by Morris [59] also differed from the present study in that they
looked at distinguishing patients with airflow obstruction from normal subjects, whereas
the present study concentrated at looking at identifying novel variables that could pick
up changes in airflow obstruction within an individual. The ages of the two groups in
Morris study were not similar (34.2 ± 9.6 yrs for the normal group compared to 54.8 ±
14.7 yrs) in the obstructed group and again it is not known what changes may occur in
the tidal breathing pattern with age.
As the present study did not include any normal subjects we are unable to state
if the variables described here can distinguish between normal subjects and patients
with COPD. This is a short coming of the present study which could easily be
addressed in future studies.
Although the previous studies had identified TPTef/Te as being able to
distinguish normal subjects from patients with airflow obstruction and although we
found similar baseline values for this variable in our patients, there was no change in
this variable following bronchodilation. This is because the timing within breaths does
not appear to change significantly after bronchodilation. Therefore it would not be
expected for time related variables to change as the flow related ones did.
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In a later study by Morris [61] the group looked at whether two variables
derived from the end of the expiration could be used in assessing airflow obstruction.
This work was based on the theory that the later stages of the expiration occurred by
passive relaxation with no active muscle activity and that therefore the decay of flow
with time reflects the compliance and resistance of the respiratory system. The slope of
the linear portion of this decay was calculated (Trs). A second variable, extrapolated
volume (EV), was also calculated by extrapolating the slope to zero flow and measuring
the area under the extrapolated line.
This approach is valid as long as the expiration is relaxed, however some
patients with more advanced disease utilise their abdominal muscles to help drive
expiration [46-47] therefore making it active not passive.
Also from the present study we have observed that not all patients show the
abrupt flow reversal that Morris [59-60] describes, some show exponential flow decay
to zero flow and others show long expiratory pauses which would complicate their
analysis.
In a third study by Williams [62] the breath to breath variability of the breathing
pattern was examined. As with the previous study they again used a mouthpiece and
heated pneumotach, there was no acclimatisation period and 12 ± 3 breaths were
analysed per subject.
To overcome the difference in breath length and maximum flow rate each
breath was scaled in respect of both the flow and time axis. The scaled breath was then
divided into two portions, pre-TPTEF (before the tidal peak expiratory flow rate) and
post-TpxEp. A linear regression line was the fitted to the decay slope in portion two.
The disadvantage of scaling the data in this way is that small changes in flow or
time related variables will be lost and the fitting of a linear regression line will again
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obscure small changes in the flow decay profile especially in the obstructed group as
this tends to be more concave than linear.
The group reported that scaling the data in this way rendered the pre-TpjEF
portion of the breath useless for estimation of airflow obstruction. They did find though
that the scaling enhanced the distinction between the different flow patterns for the post-
Tptef data and they stated that the fit of the linear regression line to this portion of data
was not important but that the slope of the line was, with a shallower slope reflecting
worse airflow obstruction.
The advantage of this approach is that in trying to describe the shape of the flow
profile a large portion of the breath is analysed and not one time point as with the
present studies variables of EF25. It maybe that a variable from the tidal breath similar
to that of FEF25-75 measured from the MEFV curve maybe more sensitive having the
advantage of describing a larger portion of the breath but not needing any scaling of the
breath.
In the previous work by both Morris and Williams a small number of breaths
have been analysed (10 - 15) with no acclimatisation period therefore making the
testing time very short. More work is needed to determine if this is sufficient to give
stable representative data (It maybe that the present study is causing itself problems
with aberrant breaths and possible drowsiness of the patients by measuring for 7
minutes when this is not needed).
Shortcomings of the present method of tidal breathing analysis include: -
• The need for defined resting conditions to achieve steady state breathing
pattern. Breathless patients may be unable to relax sufficiently to produce a
steady breathing pattern or be able to tolerate the facemask.
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• The bin averaging employed to produce the averaged breath depends on the
accuracy of the breath detection and breath alignment.
• The manual selection of breaths to exclude from analysis is still required
and this introduces an element of subjectivity in the analysis.
• The technique is not applicable to patients with very erratic breathing
patterns (highly variable flow patterns between breaths), such as Cheyne
Stokes breathing.
9.7: Practicality of the proposed tidal breathing measurement
method in the clinical setting.
9.7.1: Advantages.
The measurement protocol developed is simple to implement and the analysis is
straightforward and quick. Apart from the selection of breaths to exclude, all the
analysis is automated.
The protocol is also simple for the patients to perform, it involves no complex
breathing manoeuvres, other than a 2-3 second breath hold and does not require much
effort. It would therefore be potentially applicable to the investigation of patients who
are acutely ill or frail and unable to perform forced manoeuvres and in those in whom




The protocol requires that the patient be tested in a quiet room, which is not
always available in a busy department with limited space.
The patients tested in these studies were clinically stable. More unstable
patients may be unable to relax enough to give a steady breathing pattern or to tolerate
the facemask.
9.8: Conclusion.
In conclusion, the initial hypothesis that tidal breathing flow profiles reflect
airflow obstruction and would show changes in response to bronchodilation has been
confirmed by these studies. This work has identified three novel variables, TBEV,,
TPEF and EF25 that can be measured from tidal breathing expiratory flow profiles that
can be used to assess airflow obstruction in patients with COPD.
These three variables correlate with conventional variables, change in a
physiologically plausible way after bronchodilation, have measure-to-measure
variability and reproducibility comparable with conventional variables and correlate
with the subjective decrease in dyspnoea after bronchodilation.
The present method overcomes many but not all of the problems associated
with the measurement of forced expiration and previous attempts to quantify airflow
obstruction from tidal breathing. With careful control of measurement conditions, it
could be applied with little modification to clinical practice, and measurements are
achievable in little more time than is taken to perform conventional spirometry.
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Chapter 10: Future work.
10.1: Mechanisms behind the tidal flow profile change.
The observations of tidal breathing presented in this thesis do not themselves
contribute to a greater understanding of the underlying determinants of the tidal flow
profile. In particular the relative importance of passive mechanical relaxation processes
compared to respiratory muscle activity in determining instantaneous expiratory flow
cannot be deduced from these recordings. Others [60] have emphasised the importance
of post inspiratory braking of early expiratory flow by sustained inspiratory muscle
activity as a determinant of early expiratory flow. This mechanism is said to be reduced
in COPD, with mechanical relaxation being instead the dominant determinant of
expiratory flow, however further studies of the patterns of activation of respiratory
muscle groups during spontaneous breathing in COPD are needed to confirm or refute
this concept. Such studies would necessarily involve the measurement of additional
variables during tidal breathing including: -
• Respiratory muscle EMG, both inspiratory and expiratory.
• Intrabreath airways resistance.
• Measurement of the relative contributions of the chest wall and abdomen during
tidal breathing.
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10.2: Other patient groups.
The work described in this thesis was carried out on patients with COPD who
had previously demonstrated partial reversibility to inhaled bronchodilators. Three
other groups which would be interesting to investigate would be: -
• Patients who had symptomatic benefit from bronchodilators but no significant
response as measured by spirometric variables, to investigate if the tidal breathing
variables changed after bronchodilation.
• Patients with asthma who had significant reversibility to bronchodilators to see if
the technique was applicable to a more generalised patient population.
• Normal subjects to ensure that the technique is not too sensitive and diagnoses
reversibility in everyone.
10.3: Other study situations.
The ability to assess airflow obstruction during tidal breathing would be of
benefit in a number of situations including: -
10.3.1: Exercise.
Much research is being undertaken looking at bronchoconstriction during
exercise, and it is difficult for subjects to perform forced expiration whilst exercising.
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Comparison of tidal breathing profiles at matched levels of ventilation could be used to
study airway calibre during exercise.
10.3.2: Bronchial challenge.
At present the response of subjects to bronchial challenge with substances such
as methacholine and histamine is measured by changes in FEVi. As the measurement
ofFEVi can cause coughing and coughing can blow the challenge drug from the airway
it can lead to a falsely high PD2o (provocative dose which causes 20% drop in FEVi).
Tidal breathing measurements, on the other hand, do not cause coughing and would
overcome this problem. However changes in the analysis of the variables may be
needed to speed up the analysis time, which for the study in this thesis was done offline
and took approximately 2 minutes per 5 minutes period.
10.4: Conclusion.
The method of tidal breathing analysis presented in this thesis opens up the
possibility of generating new insights into the pathophysiology of airflow obstruction
and the effects of treatment. Such methods observe the respiratory system operating
under conditions which more closely resemble normal breathing than techniques which
depend on forced expiration. Results are therefore arguably more relevant to the
clinical condition and the limitations it imposes on patients' lives. Further studies are
needed to elucidate more clearly the underlying determinants of tidal expiratory flow
yet despite an incomplete understanding of the underlying processes, a relatively simple
method of measuring, recording and averaging tidal flow has been found to be capable
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of demonstrating significant and reproducible changes following the administration of
bronchodilators. With appropriate development the technique could be applied to study
airflow obstruction in other areas such as exercise and bronchial challenge.
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Chapter 11: Appendices.
Appendix A. Equipment specifications.
11.1: Model FR-41s Ultrasonic phase-shift flowmeter.
BRDL Ltd, Birmingham, UK.
11.1.1: Principle of operation.
The ultrasonic phase-shift transducer operates on the principle of the distortion
of a sound wave by moving air. Two transducers Ta and Tb are mounted diagonally
across a tube, through with air moves, at an angle 0.
Both transducer send and receive sound waves. If transducer Ta is driven at a
frequency f, then the time taken, At, for the sound to reach the receiving transducer T2,
positioned d cm away is: -
d
AH - 2 =
C+V cos 6
where: VcosG = the component ofmean air flow along the path d
C = the velocity of sound in air
This represents a phase-shift, 0, of the transmitted signal, where: -
2nfd.
(f)1-2
C + V cos <9
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and the difference between the two phase shifts, A(j>, equals: -
If C2» V2cos2(j> this simplifies to: -
Therefore the difference between the phase-shifts found with the ultrasound travelling
in each direction is linearly related to the mean velocity of air in the tube. Because the
velocity of sound in a gas is proportional to the square root of the temperature and
independent of pressure, the relationship above is inversely proportional to temperature.
The resulting variation in gain of the instrument corrects the volume flow rate for
changes in temperature.
11.1.2: Specifications.
Linearity: maximum deviation from true flow <2% of
reading.
Baseline stability:
Inhale : exhale < 0.2% fsd.
Temperature (ambient) < 0.2% fsd /°C.









+ 0.16% gain change.
- 0.27 % /°C.
Half of the flow is sampled at 160 Hz, giving






Appendix B: Computer Programs.
11.2: Data collection Computer Program.
A working copy of this program can be found on the enclosed CDROM.
11.3: Data Analysis Computer Program.
A working copy of this program can be found on the enclosed CDROM.
11.4: Breath Marker Algorithms.
The data analysis program looks for breath markers using the following
algorithm: -
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11.4.1: Start of Expiration.
The program first looks for a set of 3 flow data samples that are increasing in
value. It then checks to see if this data set is passing trough zero flow. The point where
this occurs is deemed as the start of expiration.
11.4.2: Start of Expiratory Pause.
After the start of expiration has been found the program skips 50 flow samples
and then checks each sample until one is found with a flow value less than 5 ml/sec.
This point is deemed the end of expiration and the start of an expiratory pause.
11.4.3: Start of Inspiration.
The program then looks for the flow to cross zero by looking for four
monotonic decreasing flow samples each one 5 samples from the preceding one. The
first sample in such a sequence is deemed the start of inspiration (figure 11.30).
The algorithm then goes back to looking for a start of expiration and loops
through this routine until the end of the flow data set.
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Sample number
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Sample ✓ Sample ✓ Sample ✓ Sample
point 1 \ point 2 \ point 3 \ point 4
Figure 11.30: Diagrammatic representation of start of inspiration algorithm.
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Appendix C: Flow meter stability.
11.5: Drift in zero flow.
When measuring flow it is important that the flowmeter is stable. The easiest
way to determine the stability of a piece of equipment is to check that the zero does not
drift. For the ultrasonic flowmeter the amount of drift in zero flow was determined
during three different situations
11.5.1: Drift Over time.
The zero flow value was measured at the start and end of a 10 minute period to
determine if the flowmeter was stable over time with no airflow through it (figure
11.31).
11.5.2: With Syringe Strokes.
Zero flow was measured before and after repeated inspirations and expirations
via a 3 litre calibrating syringe. To determine if zero drift occurred to the flow of air
(figure 11.32).
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11.5.3: With tidal breathing.
Zero flow was measured at the start and end of a 15 minute period of tidal
breathing. Zero flow was measured during 2-3 second breath holds. This was to
determine if the change in temperature that occurs throughout inspiration and expiration
caused drift in the flow meter (figure 11.33).
The data showed that no drift in zero occurred during any of the situations
investigated. Thus indicating that the ultrasonic flowmeter would be stable for the
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Figure 11.33: Flow data during the first and last minute of a 15 minute period of
tidal breathing.
Zero flow measured during 2-3 second breath hold.
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